Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rigel Pharmaceuticals, Inc. (RIGL)
USD41.30
-1.25 (-2.94%)
US NASDAQ Healthcare Biotechnology
Address
611 Gateway Boulevard 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Raul R. Rodriguez
Website
rigel.com
IPO
2000-11-29
CIK 1034842 ISIN US7665597024
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD41.30
-1.25 (-2.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
388.0K
Beta
1.18
Float Shares
18.17M
Free Float %
98.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +12.10% | +10.08% | +0.58% | -14.17% | -26.46% | -31.43% | +57.82% | +134.96% | -20.41% | +28.82% | -95.41% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (15 ratings, all time)
Buy
Price Targets & DCF
Current price
41.30
Low
2.00
-95.2%
Consensus
27.33
-33.8%
Median
38.00
-8.0%
High
42.00
+1.7%
Ratings Trend (MoM)
60% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 2 |
40.00
-3.1%
|
| All Time | 4 |
20.75
-49.8%
|
Quality scores
Altman Z-Score
1.74
Distress
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+64.2% ★ Q1'26: +10.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+1,867.7% ★ Q1'26: -30.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+118.9% ★ Q1'26: +4.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+43.9% ★ Q1'26: +22.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+44.6% ★ Q1'26: +13.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+6.5% Q1'26: +8.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.41× ★ Q1'26: 0.84× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.73M
est: 4.60M (+2.9%)
|
16.53M
est: 18.25M (-9.4%)
|
33.47M
est: 107.91M (-69.0%)
|
12.60M
est: 10.06M (+25.3%)
|
28.90M
est: 5.94M (+386.5%)
|
20.38M
est: 21.48M (-5.1%)
|
4.48M
est: 4.52M (-0.8%)
|
44.51M
est: 42.96M (+3.6%)
|
59.29M
est: 59.57M (-0.5%)
|
108.62M
est: 108.56M (+0.1%)
|
149.24M
est: 150.63M (-0.9%)
|
120.24M
est: 97.78M (+23.0%)
|
116.88M
est: 130.20M (-10.2%)
|
179.28M
est: 171.80M (+4.4%)
|
294.28M
est: 293.19M (+0.4%)
|
282.83M
280.80M – 284.85M
-3.5% YoY
|
315.17M
297.99M – 332.34M
+11.4% YoY
|
349.92M
348.81M – 351.03M
+11.0% YoY
|
358.35M
347.97M – 375.40M
+2.4% YoY
|
387.35M
376.13M – 405.78M
+8.1% YoY
|
| EBITDA |
-54.49M
est: -49.15M (-10.9%)
|
-46.74M
est: -45.76M (-2.1%)
|
-41.63M
est: -37.34M (-11.5%)
|
-79.53M
est: -64.44M (-23.4%)
|
-50.30M
est: -908.4K (-5,437.8%)
|
-63.03M
est: -3.29M (-1,818.4%)
|
-77.53M
est: -691.3K (-11,114.1%)
|
-69.89M
est: -71.81M (+2.7%)
|
-65.88M
est: -71.42M (+7.8%)
|
-27.69M
est: -16.60M (-66.7%)
|
-11.29M
est: -23.04M (+51.0%)
|
-53.87M
est: -74.78M (+28.0%)
|
-16.98M
est: -1.64M (-938.2%)
|
28.51M
est: -2.16M (+1,421.1%)
|
131.56M
est: -3.68M (+3,672.0%)
|
-3.55M
-3.58M – -3.53M
+3.5% YoY
|
-3.96M
-4.18M – -3.74M
-11.4% YoY
|
-4.40M
-4.41M – -4.38M
-11.0% YoY
|
-4.50M
-4.72M – -4.37M
-2.4% YoY
|
-4.87M
-5.10M – -4.73M
-8.1% YoY
|
| EBIT |
-56.87M
est: -52.18M (-9.0%)
|
-47.92M
est: -50.15M (+4.4%)
|
-43.05M
est: -45.60M (+5.6%)
|
-79.53M
est: -30.94M (-157.0%)
|
-51.74M
est: -962.5K (-5,275.7%)
|
-63.97M
est: -3.48M (-1,737.4%)
|
-77.99M
est: -732.6K (-10,546.5%)
|
-70.48M
est: -74.31M (+5.2%)
|
-66.56M
est: -75.01M (+11.3%)
|
-28.39M
est: -17.59M (-61.4%)
|
-12.45M
est: -24.41M (+49.0%)
|
-54.87M
est: -76.27M (+28.1%)
|
-18.22M
est: -2.87M (-535.3%)
|
26.28M
est: -3.78M (+794.6%)
|
129.15M
est: -6.46M (+2,100.0%)
|
-6.23M
-6.27M – -6.18M
+3.5% YoY
|
-6.94M
-7.32M – -6.56M
-11.4% YoY
|
-7.71M
-7.73M – -7.68M
-11.0% YoY
|
-7.89M
-8.27M – -7.66M
-2.4% YoY
|
-8.53M
-8.94M – -8.28M
-8.1% YoY
|
| Net Income |
-56.26M
est: -51.61M (-9.0%)
|
-45.26M
est: -47.23M (+4.2%)
|
-37.64M
est: -39.36M (+4.4%)
|
-74.27M
est: -64.31M (-15.5%)
|
-51.46M
est: -100.82M (+49.0%)
|
-69.22M
est: -131.90M (+47.5%)
|
-77.99M
est: -100.11M (+22.1%)
|
-70.48M
est: -72.06M (+2.2%)
|
-66.55M
est: -72.42M (+8.1%)
|
-29.74M
est: -30.49M (+2.5%)
|
-17.91M
est: -18.09M (+1.0%)
|
-58.57M
est: -37.77M (-55.1%)
|
-25.09M
est: -15.52M (-61.7%)
|
17.49M
est: 7.00M (+149.9%)
|
367.02M
est: 125.35M (+192.8%)
|
73.57M
68.24M – 78.25M
-41.3% YoY
|
71.14M
70.07M – 72.20M
-3.3% YoY
|
78.22M
55.85M – 101.59M
+10.0% YoY
|
59.85M
57.59M – 63.55M
-23.5% YoY
|
70.40M
67.75M – 74.75M
+17.6% YoY
|
| SGA |
13.08M
est: 3.49M (+274.8%)
|
12.41M
est: 13.03M (-4.7%)
|
19.55M
est: 22.59M (-13.5%)
|
21.76M
est: 7.63M (+185.4%)
|
17.81M
est: 4.50M (+295.5%)
|
20.91M
est: 16.29M (+28.4%)
|
37.83M
est: 3.43M (+1,003.8%)
|
70.00M
est: 32.57M (+114.9%)
|
74.59M
est: 45.17M (+65.1%)
|
76.60M
est: 82.32M (-6.9%)
|
91.89M
est: 114.22M (-19.5%)
|
112.45M
est: 74.15M (+51.7%)
|
105.74M
est: 90.62M (+16.7%)
|
113.06M
est: 119.57M (-5.4%)
|
115.90M
est: 204.06M (-43.2%)
|
196.85M
195.44M – 198.26M
-3.5% YoY
|
219.36M
207.41M – 231.31M
+11.4% YoY
|
243.55M
242.78M – 244.32M
+11.0% YoY
|
249.42M
242.19M – 261.29M
+2.4% YoY
|
269.60M
261.79M – 282.43M
+8.1% YoY
|
| EPS |
-3.12
est: -2.72 (-14.7%)
|
-2.07
est: -2.35 (+11.9%)
|
-1.51
est: -2.37 (+36.2%)
|
-2.57
est: -2.05 (-25.7%)
|
-5.82
est: -5.70 (-2.1%)
|
-7.33
est: -7.46 (+1.7%)
|
-6.17
est: -5.66 (-9.0%)
|
-4.40
est: -4.18 (-5.3%)
|
-4.00
est: -3.78 (-5.9%)
|
-1.80
est: -1.72 (-4.4%)
|
-1.10
est: -1.02 (-7.5%)
|
-3.40
est: -4.53 (+25.0%)
|
-1.44
est: -0.81 (-76.9%)
|
0.99
est: 0.39 (+154.5%)
|
20.40
est: 6.64 (+207.3%)
|
3.93
3.62 – 4.15
-40.8% YoY
|
3.78
3.72 – 3.83
-4.0% YoY
|
4.01
2.96 – 5.39
+6.1% YoY
|
3.18
3.06 – 3.37
-20.7% YoY
|
3.74
3.60 – 3.97
+17.6% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-07 | Citigroup | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 1/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
85.43M
OE per share TTM
4.58
Owner's Yield
15.80%
Maintenance CapEx ratio
4.03%
Maint CapEx / Avg PPE
6.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
23
Total invested
20.09M
Insider transactions (90d)
0
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SSGA FUNDS MANAGEMENT, INC. | 20.62M | 11.00% | — | 20.58M | — | 20.62M | IA | BOSTON, MASSACHUSETTS | 2022-07-11 | ↗ |
| 2 | Armistice Capital, LLC | 16.96M | 9.81% | — | 16.96M | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 3 | Steven Boyd | 16.96M | 9.81% | — | 16.96M | — | — | HC, IN | United States of America | 2023-02-14 | ↗ |
| 4 | (1) BlackRock, Inc. | 16.55M | 9.70% | 15.71M | — | 16.55M | — | HC | Delaware | 2022-02-01 | ↗ |
| 5 | Abigail P. Johnson | 15.49M | 8.96% | — | — | 15.49M | — | IN | Delaware | 2022-10-11 | ↗ |
| 6 | FMR LLC | 15.49M | 8.96% | 15.48M | — | 15.49M | — | HC | Delaware | 2022-10-11 | ↗ |
| 7 | Morgan Stanley | 14.49M | 8.30% | — | 14.47M | — | 13.00 | HC, CO | Delaware. | 2024-02-09 | ↗ |
| 8 | Morgan Stanley Capital Services LLC | 14.09M | 8.10% | — | — | — | 13.00 | BD, CO | Delaware. | 2024-02-09 | ↗ |
| 9 | Wellington Management Company LLP | 10.45M | 6.18% | — | 10.41M | — | — | IA | Massachusetts | 2021-02-04 | ↗ |
| 10 | GOLDMAN SACHS & CO. LLC | 9.37M | 5.40% | — | 9.37M | — | 9.37M | BD, IA, OO | Delaware | 2023-02-14 | ↗ |
| 11 | THE GOLDMAN SACHS GROUP, INC. | 9.37M | 5.40% | — | 9.37M | — | 9.37M | HC, CO | Delaware | 2023-02-14 | ↗ |
| 12 | Guy Levy | 9.22M | 5.30% | — | 9.22M | — | 9.22M | IN | Cayman Islands | 2023-02-22 | ↗ |
| 13 | Soleus Capital Group, LLC | 9.22M | 5.30% | — | 9.22M | — | 9.22M | OO | Cayman Islands | 2023-02-22 | ↗ |
| 14 | Soleus Capital Master Fund, L.P. | 9.22M | 5.30% | — | 9.22M | — | 9.22M | FI | Cayman Islands | 2023-02-22 | ↗ |
| 15 | Soleus Capital, LLC | 9.22M | 5.30% | — | 9.22M | — | 9.22M | OO | Cayman Islands | 2023-02-22 | ↗ |
| 16 | The Vanguard Group - 23-1945930 | 9.03M | 5.28% | — | 323.7K | 8.58M | 448.2K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 17 | Israel A. Englander | 7.59M | 4.40% | — | 7.59M | — | 7.59M | IN | — | 2022-09-22 | ↗ |
| 18 | Millennium Group Management LLC | 7.59M | 4.40% | — | 7.59M | — | 7.59M | OO | — | 2022-09-22 | ↗ |
| 19 | Millennium Management LLC | 7.59M | 4.40% | — | 7.59M | — | 7.59M | OO | — | 2022-09-22 | ↗ |
| 20 | STATE STREET CORPORATION | 3.37M | 1.95% | — | 3.19M | — | 3.37M | HC | BOSTON, MASSACHUSETTS | 2023-02-06 | ↗ |
| 21 | Wellington Group Holdings LLP | 1.41M | 0.82% | — | 1.41M | — | — | HC | Massachusetts | 2021-09-10 | ↗ |
| 22 | Wellington Investment Advisors Holdings LLP | 1.41M | 0.82% | — | 1.41M | — | — | HC | Massachusetts | 2021-09-10 | ↗ |
| 23 | Wellington Management Group LLP | 1.41M | 0.82% | — | 1.41M | — | — | HC | Massachusetts | 2021-09-10 | ↗ |
| 24 | 98-0557567 | 1.05M | 6.00% | 1.05M | — | 1.05M | — | IA, HC | Bermuda | 2024-11-08 | ↗ |
| 25 | Integrated Assets II LLC | 988.7K | 0.60% | — | 988.7K | — | 988.7K | OO | — | 2021-02-16 | ↗ |
| 26 | Millennium International Management LP | 988.7K | 0.60% | — | 988.7K | — | 988.7K | PN | — | 2021-02-16 | ↗ |
| 27 | Integrated Core Strategies (US) LLC | 39.8K | 0.00% | — | 39.8K | — | 39.8K | OO | — | 2021-02-16 | ↗ |
| 28 | Dr. Jeffrey R. Jay, M.D. | — | 0.00% | — | — | — | — | IN | USA | 2019-02-14 | ↗ |
| 29 | Great Point Partners, LLC | — | 0.00% | — | — | — | — | IA | USA | 2019-02-14 | ↗ |
| 30 | Mr. David Kroin | — | 0.00% | — | — | — | — | IN | USA | 2019-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
23
-168 vs prev Q
New positions
2
Closed positions
164
Increased
14
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 1.66M -60.7K (-3.5%) | 71.28M +22.4M (+45.9%) | 9.23% -0.418 pp | 0.00% +0.000 pp | USD16.94 +152.8% | 6 qtrs — |
| 2 | STATE STREET CORP | 1.09M +536.9K (+96.9%) | 46.74M +31.0M (+197.6%) | 6.05% +2.950 pp | 0.00% +0.001 pp | USD27.41 +56.3% | 7 qtrs — |
| 3 | VANGUARD GROUP INC | 1.04M -4.7K (-0.5%) | 44.48M +14.9M (+50.5%) | 5.76% -0.076 pp | 0.00% +0.000 pp | USD9.19 +366.1% | 7 qtrs — |
| 4 | ARMISTICE CAPITAL, LLC | 836.0K +112.0K (+15.5%) | 35.81M +15.3M (+74.6%) | 4.63% +0.587 pp | 0.43% +0.122 pp | USD15.38 +178.5% | 7 qtrs — |
| 5 | GOLDMAN SACHS GROUP INC | 671.9K -65.2K (-8.8%) | 28.78M +7.9M (+37.8%) | 3.72% -0.396 pp | 0.00% +0.001 pp | USD25.79 +66.1% | 6 qtrs — |
| 6 | MARSHALL WACE, LLP | 613.6K +12.3K (+2.0%) | 26.28M +9.2M (+54.3%) | 3.40% +0.040 pp | 0.02% +0.007 pp | USD22.59 +89.6% | 4 qtrs — |
| 7 | LSV ASSET MANAGEMENT | 544.3K +433.4K (+390.8%) | 23.31M +20.2M (+641.9%) | 3.02% +2.397 pp | 0.05% +0.044 pp | USD38.19 +12.1% | 3 qtrs — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 539.0K +64.8K (+13.7%) | 23.09M +9.7M (+71.8%) | 2.99% +0.337 pp | 0.04% +0.018 pp | USD23.66 +81.0% | 7 qtrs — |
| 9 | ACADIAN ASSET MANAGEMENT LLC | 493.6K -192.1K (-28.0%) | 21.13M +1.7M (+8.9%) | 2.74% -1.098 pp | 0.03% +0.001 pp | USD13.74 +211.7% | 7 qtrs — |
| 10 | MILLENNIUM MANAGEMENT LLC | 431.5K +326.2K (+309.7%) | 18.48M +15.5M (+519.5%) | 2.39% +1.803 pp | 0.01% +0.007 pp | USD38.60 +11.0% | 7 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 424.3K +591.0 (+0.1%) | 18.18M +6.2M (+51.4%) | 2.35% -0.017 pp | 0.00% +0.000 pp | USD9.36 +357.6% | 7 qtrs — |
| 12 | D. E. SHAW & CO., INC. | 424.3K +117.8K (+38.4%) | 18.17M +9.5M (+109.3%) | 2.35% +0.639 pp | 0.01% +0.005 pp | USD32.36 +32.4% | 2 qtrs — |
| 13 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 413.7K +227.3K (+122.0%) | 17.72M +12.4M (+235.6%) | 2.29% +1.252 pp | 0.01% +0.007 pp | USD35.79 +19.7% | 3 qtrs — |
| 14 | SOLEUS CAPITAL MANAGEMENT, L.P. | 300.0K -30.0K (-9.1%) | 12.85M +3.5M (+37.5%) | 1.66% -0.182 pp | 0.47% +0.003 pp | USD9.87 +333.9% | 7 qtrs — |
| 15 | QUBE RESEARCH & TECHNOLOGIES LTD | 288.3K -72.7K (-20.1%) | 12.35M +2.1M (+20.7%) | 1.60% -0.420 pp | 0.01% +0.002 pp | USD23.07 +85.7% | 7 qtrs — |
| 16 | HILLSDALE INVESTMENT MANAGEMENT INC. | 282.6K -1.8K (-0.6%) | 12.10M +4.0M (+50.2%) | 1.57% -0.024 pp | 0.33% +0.091 pp | USD18.24 +134.8% | 6 qtrs — |
| 17 | DIMENSIONAL FUND ADVISORS LP | 276.8K +67.4K (+32.2%) | 11.86M +5.9M (+99.8%) | 1.53% +0.364 pp | 0.00% +0.001 pp | USD26.24 +63.2% | 5 qtrs — |
| 18 | JANE STREET GROUP, LLC | 275.9K -46.0K (-14.3%) | 11.82M +2.7M (+29.6%) | 1.53% -0.270 pp | 0.00% +0.000 pp | USD27.81 +54.0% | 7 qtrs — |
| 19 | TWO SIGMA INVESTMENTS, LP | 271.2K +50.9K (+23.1%) | 11.62M +5.4M (+86.1%) | 1.50% +0.272 pp | 0.02% +0.007 pp | USD29.61 +44.6% | 5 qtrs — |
| 20 | NUVEEN, LLC | 258.9K +125.4K (+94.0%) | 11.09M +7.3M (+193.3%) | 1.44% +0.689 pp | 0.00% +0.002 pp | USD31.23 +37.1% | 4 qtrs — |
| 21 | AMERICAN CENTURY COMPANIES INC | 254.5K +254.5K (+100.0%) | 10.90M +10.9M (+100.0%) | 1.41% +1.411 pp | 0.01% +0.006 pp | USD42.83 +0.0% | 3 qtrs — |
| 22 | CM MANAGEMENT, LLC | 225.0K +— (+0.0%) | 9.64M +3.3M (+51.2%) | 1.25% -0.011 pp | 8.12% +2.810 pp | USD16.23 +163.9% | 6 qtrs — |
| 23 | GLOBEFLEX CAPITAL L P | 217.8K +209.0 (+0.1%) | 9.33M +3.2M (+51.3%) | 1.21% -0.009 pp | 1.43% +0.479 pp | USD20.48 +109.1% | 6 qtrs — |
| 24 | TREXQUANT INVESTMENT LP | 197.1K +30.0K (+18.0%) | 8.44M +3.7M (+78.3%) | 1.09% +0.159 pp | 0.08% +0.027 pp | USD30.54 +40.2% | 5 qtrs — |
| 25 | CITADEL ADVISORS LLC | 185.4K +99.0K (+114.4%) | 7.94M +5.5M (+224.2%) | 1.03% +0.545 pp | 0.00% +0.001 pp | USD36.07 +18.7% | 2 qtrs — |
| 26 | MORGAN STANLEY | 166.5K +20.2K (+13.8%) | 7.13M +3.0M (+72.1%) | 0.92% +0.105 pp | 0.00% +0.000 pp | USD13.22 +224.0% | 7 qtrs — |
| 27 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 148.6K -31.2K (-17.3%) | 6.37M +1.3M (+25.0%) | 0.82% -0.181 pp | 0.00% +0.000 pp | USD20.39 +110.1% | 7 qtrs — |
| 28 | PRUDENTIAL FINANCIAL INC | 135.4K -29.9K (-18.1%) | 5.80M +1.1M (+23.8%) | 0.75% -0.174 pp | 0.01% +0.001 pp | USD24.55 +74.5% | 7 qtrs — |
| 29 | NORTHERN TRUST CORP | 129.0K -8.7K (-6.3%) | 5.53M +1.6M (+41.7%) | 0.72% -0.055 pp | 0.00% +0.000 pp | USD8.90 +381.2% | 7 qtrs — |
| 30 | ZACKS INVESTMENT MANAGEMENT | 119.1K -9.1K (-7.1%) | 5.10M +1.5M (+40.4%) | 0.66% -0.057 pp | 0.04% +0.011 pp | USD17.30 +147.6% | 7 qtrs — |
| 31 | BANK OF AMERICA CORP /DE/ | 117.0K +41.5K (+55.0%) | 5.01M +2.9M (+134.3%) | 0.65% +0.226 pp | 0.00% +0.000 pp | USD26.30 +62.9% | 7 qtrs — |
| 32 | AQR CAPITAL MANAGEMENT LLC | 109.7K +53.1K (+93.9%) | 4.70M +3.1M (+193.1%) | 0.61% +0.292 pp | 0.00% +0.001 pp | USD34.41 +24.5% | 4 qtrs — |
| 33 | BANK OF NEW YORK MELLON CORP | 108.3K +10.4K (+10.6%) | 4.64M +1.9M (+67.3%) | 0.60% +0.053 pp | 0.00% +0.000 pp | USD17.11 +150.3% | 7 qtrs — |
| 34 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 108.0K +95.6K (+772.0%) | 4.63M +4.3M (+1,218.3%) | 0.60% +0.529 pp | 0.03% +0.024 pp | USD41.17 +4.0% | 2 qtrs — |
| 35 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 108.0K -120.4K (-52.7%) | 4.62M -1.8M (-28.5%) | 0.60% -0.679 pp | 0.01% -0.008 pp | USD18.28 +134.3% | 7 qtrs — |
| 36 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 94.2K +72.5K (+334.1%) | 4.03M +3.4M (+556.3%) | 0.52% +0.401 pp | 0.00% +0.000 pp | USD36.08 +18.7% | 7 qtrs — |
| 37 | RITHOLTZ WEALTH MANAGEMENT | 80.6K +73.0K (+961.3%) | 3.45M +3.2M (+1,504.5%) | 0.45% +0.404 pp | 0.06% +0.059 pp | USD41.46 +3.3% | 2 qtrs — |
| 38 | EMPIRE FINANCIAL MANAGEMENT COMPANY, LLC | 76.4K -13.1K (-14.6%) | 3.27M +738.3K (+29.1%) | 0.42% -0.077 pp | 0.71% +0.131 pp | USD25.37 +68.8% | 6 qtrs — |
| 39 | BARCLAYS PLC | 75.4K +48.0K (+175.6%) | 3.23M +2.8M (+629.5%) | 0.42% +0.265 pp | 0.00% +0.001 pp | USD33.65 +27.3% | 6 qtrs — |
| 40 | RUSSELL INVESTMENTS GROUP, LTD. | 73.9K -44.1K (-37.4%) | 3.16M -179.5K (-5.4%) | 0.41% -0.250 pp | 0.00% 0.000 pp | USD26.19 +63.5% | 7 qtrs — |
| 41 | BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC | 71.6K -2.6K (-3.5%) | 3.07M +964.1K (+45.9%) | 0.40% -0.018 pp | 0.02% +0.006 pp | USD18.73 +128.7% | 3 qtrs — |
| 42 | OPALEYE MANAGEMENT INC. | 70.0K +32.2K (+85.2%) | 3.00M +1.9M (+180.1%) | 0.39% +0.177 pp | 0.40% +0.244 pp | USD35.00 +22.4% | 2 qtrs — |
| 43 | FMR LLC | 67.8K +8.8K (+14.8%) | 2.91M +1.2M (+73.6%) | 0.38% +0.046 pp | 0.00% +0.000 pp | USD29.43 +45.5% | 7 qtrs — |
| 44 | PACER ADVISORS, INC. | 65.5K -12.0K (-15.5%) | 2.81M +610.5K (+27.8%) | 0.36% -0.070 pp | 0.01% +0.002 pp | USD28.33 +51.2% | 4 qtrs — |
| 45 | FIRST TRUST ADVISORS LP | 64.8K +7.2K (+12.5%) | 2.78M +1.1M (+70.1%) | 0.36% +0.037 pp | 0.00% +0.001 pp | USD29.94 +43.1% | 2 qtrs — |
| 46 | WELLS FARGO & COMPANY/MN | 62.0K +1.2K (+1.9%) | 2.66M +932.2K (+54.1%) | 0.34% +0.004 pp | 0.00% +0.000 pp | USD18.52 +131.3% | 7 qtrs — |
| 47 | SCHRODER INVESTMENT MANAGEMENT GROUP | 61.0K -10.8K (-15.0%) | 2.61M +549.6K (+26.6%) | 0.34% -0.063 pp | 0.00% +0.000 pp | USD28.33 +51.2% | 2 qtrs — |
| 48 | WELLINGTON MANAGEMENT GROUP LLP | 57.0K -4.8K (-7.7%) | 2.44M +691.4K (+39.5%) | 0.32% -0.029 pp | 0.00% +0.000 pp | USD17.38 +146.4% | 5 qtrs — |
| 49 | MAN GROUP PLC | 56.7K +33.9K (+148.3%) | 2.43M +1.8M (+275.3%) | 0.31% +0.187 pp | 0.00% +0.003 pp | USD33.13 +29.3% | 7 qtrs — |
| 50 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 55.2K +55.2K (+100.0%) | 2.36M +2.4M (+100.0%) | 0.31% +0.306 pp | 0.00% +0.004 pp | USD42.83 +0.0% | 1 qtrs NEW |
| 51 | SQUAREPOINT OPS LLC | 53.6K -119.1K (-69.0%) | 2.29M -2.6M (-53.1%) | 0.30% -0.668 pp | 0.00% -0.003 pp | USD25.30 +69.3% | 7 qtrs — |
| 52 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 53.0K -1.8K (-3.2%) | 2.27M +718.6K (+46.3%) | 0.29% -0.012 pp | 0.00% +0.000 pp | USD18.91 +126.5% | 4 qtrs — |
| 53 | HUSSMAN STRATEGIC ADVISORS, INC. | 52.5K +52.5K (+100.0%) | 2.25M +2.2M (+100.0%) | 0.29% +0.291 pp | 0.54% +0.544 pp | USD42.83 +0.0% | 1 qtrs NEW |
| 54 | HENNION & WALSH ASSET MANAGEMENT, INC. | 52.2K +52.2K (+100.0%) | 2.24M +2.2M (+100.0%) | 0.29% +0.289 pp | 0.08% +0.077 pp | USD42.83 +0.0% | 1 qtrs NEW |
| 55 | WOODLINE PARTNERS LP | 50.0K +50.0K (+100.0%) | 2.14M +2.1M (+100.0%) | 0.28% +0.277 pp | 0.01% +0.008 pp | USD42.83 +0.0% | 1 qtrs NEW |
| 56 | LOS ANGELES CAPITAL MANAGEMENT LLC | 66.1K -3.0K (-4.4%) | 2.09M +132.0K (+6.7%) | 0.37% -0.020 pp | 0.01% +0.001 pp | USD12.45 +244.0% | 7 qtrs — |
| 57 | UBS GROUP AG | 46.4K -54.2K (-53.8%) | 1.99M -861.0K (-30.2%) | 0.26% -0.305 pp | 0.00% 0.000 pp | USD21.27 +101.4% | 6 qtrs — |
| 58 | RANGE FINANCIAL GROUP LLC | 45.9K +561.0 (+1.2%) | 1.97M +682.0K (+53.1%) | 0.25% +0.001 pp | 0.68% +0.217 pp | USD28.51 +50.2% | 2 qtrs — |
| 59 | JACOBS LEVY EQUITY MANAGEMENT, INC | 44.5K -6.3K (-12.3%) | 1.91M +467.7K (+32.5%) | 0.25% -0.037 pp | 0.01% +0.002 pp | USD10.06 +325.7% | 7 qtrs — |
| 60 | RAYMOND JAMES FINANCIAL INC | 43.8K +236.0 (+0.5%) | 1.87M +641.1K (+52.0%) | 0.24% -0.001 pp | 0.00% +0.000 pp | USD28.39 +50.9% | 3 qtrs — |
| 61 | RAFFERTY ASSET MANAGEMENT, LLC | 43.1K +29.4K (+215.1%) | 1.85M +1.5M (+376.4%) | 0.24% +0.163 pp | 0.01% +0.005 pp | USD34.95 +22.5% | 4 qtrs — |
| 62 | FRANKLIN RESOURCES INC | 41.0K +4.4K (+12.1%) | 1.76M +720.3K (+69.5%) | 0.23% +0.023 pp | 0.00% +0.000 pp | USD22.93 +86.8% | 6 qtrs — |
| 63 | RUFFER LLP | 37.2K +37.2K (+100.0%) | 1.60M +1.6M (+100.0%) | 0.21% +0.207 pp | 0.07% +0.073 pp | USD42.83 +0.0% | 1 qtrs NEW |
| 64 | SEGALL BRYANT & HAMILL, LLC | 37.3K +1.3K (+3.5%) | 1.60M +575.8K (+56.5%) | 0.21% +0.005 pp | 0.02% +0.008 pp | USD17.70 +142.0% | 5 qtrs — |
| 65 | JPMORGAN CHASE & CO | 37.0K +2.1K (+5.9%) | 1.59M +594.9K (+60.1%) | 0.21% +0.010 pp | 0.00% +0.000 pp | USD25.81 +65.9% | 7 qtrs — |
| 66 | JANUS HENDERSON GROUP PLC | 36.2K -194.5K (-84.3%) | 1.55M -5.0M (-76.3%) | 0.20% -1.089 pp | 0.00% -0.002 pp | USD28.33 +51.2% | 2 qtrs — |
| 67 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 35.0K +35.0K (+100.0%) | 1.50M +1.5M (+100.0%) | 0.19% +0.194 pp | 0.00% +0.002 pp | USD42.83 +0.0% | 1 qtrs NEW |
| 68 | INVESCO LTD. | 34.9K +6.8K (+24.1%) | 1.50M +698.7K (+87.7%) | 0.19% +0.036 pp | 0.00% +0.000 pp | USD25.13 +70.4% | 7 qtrs — |
| 69 | DIADEMA PARTNERS LP | 30.0K +30.0K (+100.0%) | 1.28M +1.3M (+100.0%) | 0.17% +0.166 pp | 0.22% +0.221 pp | USD42.83 +0.0% | 1 qtrs NEW |
| 70 | CREDIT AGRICOLE S A | 28.8K +28.8K (+100.0%) | 1.23M +1.2M (+100.0%) | 0.16% +0.160 pp | 0.00% +0.003 pp | USD42.83 +0.0% | 1 qtrs NEW |
| 71 | Y-INTERCEPT (HONG KONG) LTD | 28.3K +4.4K (+18.6%) | 1.21M +535.5K (+79.4%) | 0.16% +0.024 pp | 0.03% +0.011 pp | USD30.61 +39.9% | 2 qtrs — |
| 72 | ALPS ADVISORS INC | 27.0K +6.6K (+32.4%) | 1.16M +579.0K (+100.2%) | 0.15% +0.036 pp | 0.01% +0.004 pp | USD31.88 +34.3% | 5 qtrs — |
| 73 | EAM INVESTORS, LLC | 27.0K -8.9K (-24.9%) | 1.16M +138.2K (+13.6%) | 0.15% -0.051 pp | 0.13% +0.012 pp | USD28.33 +51.2% | 2 qtrs — |
| 74 | SEI INVESTMENTS CO | 26.8K -33.2K (-55.4%) | 1.15M -552.5K (-32.5%) | 0.15% -0.187 pp | 0.00% -0.001 pp | USD28.33 +51.2% | 4 qtrs — |
| 75 | WAKEFIELD ASSET MANAGEMENT LLLP | 25.7K +25.7K (+100.0%) | 1.10M +1.1M (+100.0%) | 0.14% +0.142 pp | 0.30% +0.298 pp | USD42.83 +0.0% | 1 qtrs NEW |
| 76 | CANADA PENSION PLAN INVESTMENT BOARD | 24.2K +24.2K (+100.0%) | 1.04M +1.0M (+100.0%) | 0.13% +0.134 pp | 0.00% +0.001 pp | USD42.83 +0.0% | 1 qtrs NEW |
| 77 | MACKENZIE FINANCIAL CORP | 23.7K -5.6K (-19.2%) | 1.01M +181.6K (+21.9%) | 0.13% -0.033 pp | 0.00% +0.000 pp | USD18.73 +128.7% | 3 qtrs — |
| 78 | RHUMBLINE ADVISERS | 23.0K -3.5K (-13.1%) | 983.0K +235.0K (+31.4%) | 0.13% -0.020 pp | 0.00% +0.000 pp | USD9.57 +347.5% | 7 qtrs — |
| 79 | SIERRA SUMMIT ADVISORS LLC | 22.4K -7.8K (-25.8%) | 959.4K +104.3K (+12.2%) | 0.12% -0.045 pp | 0.15% +0.017 pp | USD18.73 +128.7% | 3 qtrs — |
| 80 | GRAHAM CAPITAL MANAGEMENT, L.P. | 21.0K -2.5K (-10.7%) | 898.0K +232.7K (+35.0%) | 0.12% -0.015 pp | 0.02% +0.011 pp | USD20.50 +108.9% | 5 qtrs — |
| 81 | PRINCIPAL FINANCIAL GROUP INC | 20.8K +6.4K (+44.9%) | 891.0K +484.3K (+119.1%) | 0.12% +0.035 pp | 0.00% +0.000 pp | USD26.20 +63.5% | 3 qtrs — |
| 82 | ALLIANCEBERNSTEIN L.P. | 18.9K -14.2K (-43.0%) | 809.2K -129.5K (-13.8%) | 0.10% -0.081 pp | 0.00% +0.000 pp | USD9.41 +355.2% | 7 qtrs — |
| 83 | ENGINEERS GATE MANAGER LP | 18.2K -7.8K (-30.1%) | 780.9K +42.5K (+5.7%) | 0.10% -0.045 pp | 0.01% +0.001 pp | USD28.33 +51.2% | 2 qtrs — |
| 84 | TWO SIGMA ADVISERS, LP | 16.2K +7.9K (+94.5%) | 693.8K +457.8K (+194.1%) | 0.09% +0.043 pp | 0.00% +0.001 pp | USD27.08 +58.2% | 7 qtrs — |
| 85 | PROFUND ADVISORS LLC | 15.9K +15.9K (+100.0%) | 680.1K +680.1K (+100.0%) | 0.09% +0.088 pp | 0.02% +0.021 pp | USD42.83 +0.0% | 1 qtrs NEW |
| 86 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 15.5K +15.5K (+100.0%) | 665.7K +665.7K (+100.0%) | 0.09% +0.086 pp | 0.01% +0.007 pp | USD42.83 +0.0% | 1 qtrs NEW |
| 87 | STRS OHIO | 15.4K -2.7K (-14.9%) | 659.6K +146.8K (+28.6%) | 0.09% -0.016 pp | 0.00% +0.001 pp | USD12.52 +242.1% | 7 qtrs — |
| 88 | WINTON GROUP LTD | 15.3K +4.2K (+37.9%) | 654.7K +340.6K (+108.4%) | 0.08% +0.023 pp | 0.02% +0.011 pp | USD32.31 +32.6% | 2 qtrs — |
| 89 | DEUTSCHE BANK AG\ | 14.7K +570.0 (+4.0%) | 627.7K +228.6K (+57.3%) | 0.08% +0.003 pp | 0.00% +0.000 pp | USD14.71 +191.2% | 7 qtrs — |
| 90 | SG AMERICAS SECURITIES, LLC | 12.8K +5.8K (+82.0%) | 547.0K +348.0K (+174.9%) | 0.07% +0.032 pp | 0.00% +0.000 pp | USD34.86 +22.9% | 7 qtrs — |
| 91 | VIRTU FINANCIAL LLC | 12.6K -7.3K (-36.7%) | 541.0K -24.0K (-4.2%) | 0.07% -0.042 pp | 0.02% -0.011 pp | USD28.33 +51.2% | 2 qtrs — |
| 92 | HSBC HOLDINGS PLC | 12.4K +1.9K (+17.8%) | 536.7K +234.5K (+77.6%) | 0.07% +0.010 pp | 0.00% +0.000 pp | USD30.52 +40.3% | 2 qtrs — |
| 93 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 12.5K -10.0K (-44.3%) | 536.2K -100.3K (-15.8%) | 0.07% -0.056 pp | 0.01% -0.002 pp | USD8.41 +409.3% | 7 qtrs — |
| 94 | XTX TOPCO LTD | 12.5K -1.4K (-10.2%) | 534.0K +140.7K (+35.8%) | 0.07% -0.009 pp | 0.01% -0.006 pp | USD28.33 +51.2% | 7 qtrs — |
| 95 | QUANTINNO CAPITAL MANAGEMENT LP | 12.4K +1.6K (+14.4%) | 530.7K +223.8K (+72.9%) | 0.07% +0.008 pp | 0.00% +0.000 pp | USD30.15 +42.1% | 2 qtrs — |
| 96 | STATE OF WISCONSIN INVESTMENT BOARD | 12.0K -12.0K (-50.1%) | 512.2K -166.6K (-24.5%) | 0.07% -0.068 pp | 0.00% 0.000 pp | USD16.66 +157.1% | 6 qtrs — |
| 97 | JACKSON CREEK INVESTMENT ADVISORS LLC | 11.9K -169.0 (-1.4%) | 509.0K +167.0K (+48.8%) | 0.07% -0.002 pp | 0.15% +0.051 pp | USD17.99 +138.1% | 4 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.67
Neutral
Ratio by volume
1.39
Neutral
Buys
8
Sells
12
Shares acquired
224.4K
Shares disposed
161.9K
Cash buys
—
Cash sales
—
Net activity
+62,450
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-20 | MOOS WALTER H | Director | M-Exempt | A | Common Stock | 4,000 | 24.00 | 96.0K | 16,722 | D | ↗ |
| 2026-02-17 | Schorno Dean L | Officer | A-Award | A | Common Stock | 20,636 | 0.00 | — | 76,337 | D | ↗ |
| 2026-02-17 | Santos David A | Officer | A-Award | A | Common Stock | 19,430 | 0.00 | — | 62,870 | D | ↗ |
| 2026-02-17 | Rojkjaer Lisa | Officer | A-Award | A | Common Stock | 18,894 | 0.00 | — | 34,853 | D | ↗ |
| 2026-02-17 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Common Stock | 53,915 | 0.00 | — | 282,017 | D | ↗ |
| 2026-02-17 | Furey Raymond J. | Officer | A-Award | A | Common Stock | 19,497 | 0.00 | — | 51,813 | D | ↗ |
| 2026-02-10 | Schorno Dean L | Officer | F-InKind | D | Common Stock | 3,546 | 34.62 | 122.8K | 55,701 | D | ↗ |
| 2026-02-10 | Santos David A | Officer | F-InKind | D | Common Stock | 3,546 | 34.62 | 122.8K | 43,440 | D | ↗ |
| 2026-02-10 | Rojkjaer Lisa | Officer | F-InKind | D | Common Stock | 3,758 | 34.62 | 130.1K | 15,959 | D | ↗ |
| 2026-02-10 | RODRIGUEZ RAUL R | Director / Officer | F-InKind | D | Common Stock | 7,607 | 34.62 | 263.4K | 228,102 | D | ↗ |
| 2026-02-10 | Furey Raymond J. | Officer | F-InKind | D | Common Stock | 3,546 | 34.62 | 122.8K | 32,316 | D | ↗ |
| 2026-02-02 | Schorno Dean L | Officer | F-InKind | D | Common Stock | 5,488 | 36.01 | 197.6K | 59,247 | D | ↗ |
| 2026-02-02 | Santos David A | Officer | F-InKind | D | Common Stock | 5,718 | 36.01 | 205.9K | 46,986 | D | ↗ |
| 2026-02-02 | RODRIGUEZ RAUL R | Director / Officer | F-InKind | D | Common Stock | 14,110 | 36.01 | 508.1K | 235,709 | D | ↗ |
| 2026-02-02 | Furey Raymond J. | Officer | F-InKind | D | Common Stock | 3,968 | 36.01 | 142.9K | 35,862 | D | ↗ |
| 2026-02-01 | MILLER MICHAEL PATRICK | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 34.86 | 418.3K | 12,000 | D | ↗ |
| 2026-01-26 | RODRIGUEZ RAUL R | Director / Officer | M-Exempt | A | Common Stock | 40,000 | 27.40 | 1.10M | 285,243 | D | ↗ |
| 2025-12-22 | Schorno Dean L | Officer | M-Exempt | A | Common Stock | 1,987 | 20.00 | 39.7K | 59,722 | D | ↗ |
| 2025-09-15 | Schorno Dean L | Officer | A-Award | A | Employee Stock Option (right to buy) | 7,394 | 22.49 | 166.3K | 7,394 | D | ↗ |
| 2025-09-15 | Santos David A | Officer | A-Award | A | Employee Stock Option (right to buy) | 7,394 | 22.49 | 166.3K | 7,394 | D | ↗ |
| 2025-09-15 | Rojkjaer Lisa | Officer | A-Award | A | Employee Stock Option (right to buy) | 7,394 | 22.49 | 166.3K | 7,394 | D | ↗ |
| 2025-09-15 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 31,700 | 22.49 | 712.9K | 31,700 | D | ↗ |
| 2025-09-15 | Furey Raymond J. | Officer | A-Award | A | Employee Stock Option (right to buy) | 7,394 | 22.49 | 166.3K | 7,394 | D | ↗ |
| 2025-05-23 | Wasman Jane | Director | A-Award | A | Stock Option (Right to Buy) | 3,000 | 18.95 | 56.9K | 3,000 | D | ↗ |
| 2025-05-23 | MOOS WALTER H | Director | A-Award | A | Stock Option (Right to Buy) | 3,000 | 18.95 | 56.9K | 3,000 | D | ↗ |
| 2025-05-23 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 3,000 | 18.95 | 56.9K | 3,000 | D | ↗ |
| 2025-05-23 | HANNAH ALISON L. | Director | A-Award | A | Stock Option (Right to Buy) | 3,000 | 18.95 | 56.9K | 3,000 | D | ↗ |
| 2025-05-23 | Frohlich Mark W | Director | A-Award | A | Common Stock | 1,250 | 0.00 | — | 1,250 | D | ↗ |
| 2025-05-23 | Ali-Jackson Kamil | Director | A-Award | A | Common Stock | 2,500 | 0.00 | — | 9,375 | D | ↗ |
| 2025-03-17 | Schorno Dean L | Officer | A-Award | A | Employee Stock Option (right to buy) | 5,625 | 35.40 | 199.1K | 5,625 | D | ↗ |
| 2025-03-17 | Santos David A | Officer | A-Award | A | Employee Stock Option (right to buy) | 6,875 | 35.40 | 243.4K | 6,875 | D | ↗ |
| 2025-03-17 | Rojkjaer Lisa | Officer | A-Award | A | Employee Stock Option (right to buy) | 9,375 | 14.90 | 139.7K | 9,375 | D | ↗ |
| 2025-03-17 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 26,250 | 35.40 | 929.3K | 26,250 | D | ↗ |
| 2025-03-17 | Furey Raymond J. | Officer | A-Award | A | Employee Stock Option (right to buy) | 7,850 | 12.70 | 99.7K | 7,850 | D | ↗ |
| 2025-03-06 | Frohlich Mark W | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 19.70 | 236.4K | 12,000 | D | ↗ |
| 2025-02-05 | Schorno Dean L | Officer | S-Sale | D | Common Stock | 1,734 | 21.93 | 38.0K | 57,235 | D | ↗ |
| 2025-02-05 | Santos David A | Officer | S-Sale | D | Common Stock | 1,796 | 21.93 | 39.4K | 51,704 | D | ↗ |
| 2025-02-05 | RODRIGUEZ RAUL R | Director / Officer | S-Sale | D | Common Stock | 4,400 | 21.93 | 96.5K | 239,454 | D | ↗ |
| 2025-02-05 | Furey Raymond J. | Officer | S-Sale | D | Common Stock | 1,339 | 21.93 | 29.4K | 38,830 | D | ↗ |
| 2025-02-04 | Schorno Dean L | Officer | S-Sale | D | Common Stock | 2,036 | 20.92 | 42.6K | 58,969 | D | ↗ |
| 2025-02-04 | Santos David A | Officer | S-Sale | D | Common Stock | 2,125 | 20.92 | 44.5K | 53,500 | D | ↗ |
| 2025-02-04 | RODRIGUEZ RAUL R | Director / Officer | S-Sale | D | Common Stock | 4,952 | 20.92 | 103.6K | 243,854 | D | ↗ |
| 2025-02-04 | Furey Raymond J. | Officer | S-Sale | D | Common Stock | 1,448 | 20.92 | 30.3K | 40,169 | D | ↗ |
| 2025-01-29 | Schorno Dean L | Officer | A-Award | A | Common Stock | 19,717 | 0.00 | — | 61,005 | D | ↗ |
| 2025-01-29 | Santos David A | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 14,788 | 22.49 | 332.6K | 14,788 | D | ↗ |
| 2025-01-29 | Rojkjaer Lisa | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 14,788 | 22.49 | 332.6K | 14,788 | D | ↗ |
| 2025-01-29 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 63,400 | 22.49 | 1.43M | 63,400 | D | ↗ |
| 2025-01-29 | Furey Raymond J. | Officer | A-Award | A | Common Stock | 19,717 | 0.00 | — | 41,617 | D | ↗ |
| 2025-01-24 | RODRIGUEZ RAUL R | Director / Officer | M-Exempt | A | Common Stock | 45,000 | 21.40 | 963.0K | 250,584 | D | ↗ |
| 2024-11-25 | Schorno Dean L | Officer | A-Award | A | Employee Stock Option (right to buy) | 6,250 | 18.70 | 116.9K | 6,250 | D | ↗ |
| 2024-11-25 | Santos David A | Officer | A-Award | A | Employee Stock Option (right to buy) | 8,000 | 18.70 | 149.6K | 8,000 | D | ↗ |
| 2024-11-25 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 18.70 | 561.0K | 30,000 | D | ↗ |
| 2024-08-30 | Schorno Dean L | Officer | A-Award | A | Employee Stock Option (right to buy) | 10,000 | 24.20 | 242.0K | 10,000 | — | ↗ |
| 2024-08-30 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 32,500 | 24.20 | 786.5K | 32,500 | — | ↗ |
| 2024-05-25 | Wasman Jane | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.91 | 27.2K | 30,000 | — | ↗ |
| 2024-05-25 | MOOS WALTER H | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.91 | 27.2K | 30,000 | — | ↗ |
| 2024-05-25 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.91 | 27.2K | 30,000 | — | ↗ |
| 2024-05-25 | Kotzin Brian L. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.91 | 27.2K | 30,000 | — | ↗ |
| 2024-05-25 | HANNAH ALISON L. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.91 | 27.2K | 30,000 | — | ↗ |
| 2024-05-25 | Ali-Jackson Kamil | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 68,750 | — | ↗ |
| 2024-03-27 | Rojkjaer Lisa | Officer | A-Award | A | Employee Stock Option (right to buy) | 187,500 | 1.49 | 279.4K | 187,500 | — | ↗ |
| 2024-02-28 | Schorno Dean L | Officer | A-Award | A | Employee Stock Option (right to buy) | 78,500 | 1.27 | 99.7K | 78,500 | — | ↗ |
| 2024-02-28 | Santos David A | Officer | A-Award | A | Employee Stock Option (right to buy) | 80,000 | 1.87 | 149.6K | 80,000 | — | ↗ |
| 2024-02-28 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 1.27 | 381.0K | 300,000 | — | ↗ |
| 2024-02-28 | Furey Raymond J. | Officer | A-Award | A | Employee Stock Option (right to buy) | 93,750 | 0.90 | 84.0K | 93,750 | — | ↗ |
| 2024-02-05 | Schorno Dean L | Officer | S-Sale | D | Common Stock | 7,027 | 1.14 | 8.0K | 402,891 | — | ↗ |
| 2024-02-05 | Santos David A | Officer | S-Sale | D | Common Stock | 8,918 | 1.14 | 10.2K | 349,093 | — | ↗ |
| 2024-02-05 | RODRIGUEZ RAUL R | Director / Officer | S-Sale | D | Common Stock | 30,545 | 1.14 | 34.8K | 2,036,629 | — | ↗ |
| 2024-02-02 | Schorno Dean L | Officer | S-Sale | D | Common Stock | 5,601 | 1.13 | 6.3K | 409,918 | — | ↗ |
| 2024-02-02 | Santos David A | Officer | S-Sale | D | Common Stock | 5,601 | 1.13 | 6.3K | 358,011 | — | ↗ |
| 2024-02-02 | RODRIGUEZ RAUL R | Director / Officer | S-Sale | D | Common Stock | 22,349 | 1.13 | 25.3K | 2,067,174 | — | ↗ |
| 2024-01-23 | Schorno Dean L | Officer | A-Award | A | Common Stock | 209,000 | 0.00 | — | 415,519 | — | ↗ |
| 2024-01-23 | Santos David A | Officer | A-Award | A | Common Stock | 209,000 | 0.00 | — | 363,612 | — | ↗ |
| 2024-01-23 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Common Stock | 400,000 | 0.00 | — | 2,089,523 | — | ↗ |
| 2024-01-23 | Furey Raymond J. | Officer | A-Award | A | Common Stock | 209,000 | 0.00 | — | 214,000 | — | ↗ |
| 2023-05-26 | Wasman Jane | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.32 | 39.6K | 30,000 | — | ↗ |
| 2023-05-26 | MOOS WALTER H | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 77,222 | — | ↗ |
| 2023-05-26 | LYONS GARY A | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.32 | 39.6K | 30,000 | — | ↗ |
| 2023-05-26 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.32 | 39.6K | 30,000 | — | ↗ |
| 2023-05-26 | Kotzin Brian L. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.32 | 39.6K | 30,000 | — | ↗ |
| 2023-05-26 | HANNAH ALISON L. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.32 | 39.6K | 30,000 | — | ↗ |
| 2023-05-26 | Ali-Jackson Kamil | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 43,750 | — | ↗ |
| 2023-02-06 | RODRIGUEZ RAUL R | Director / Officer | S-Sale | D | Common Stock | 20,340 | 1.75 | 35.6K | 1,680,713 | — | ↗ |
| 2023-02-02 | Schorno Dean L | Officer | S-Sale | D | Common Stock | 5,389 | 1.66 | 8.9K | 196,519 | — | ↗ |
| 2023-02-02 | Santos David A | Officer | S-Sale | D | Common Stock | 5,388 | 1.66 | 8.9K | 144,612 | — | ↗ |
| 2023-02-02 | Dummer Wolfgang | Officer | S-Sale | D | Common Stock | 5,389 | 1.66 | 8.9K | 72,459 | — | ↗ |
| 2023-01-26 | Schorno Dean L | Director / Officer | A-Award | A | Common Stock | 63,000 | 0.00 | — | 201,908 | — | ↗ |
| 2023-01-26 | Santos David A | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 2.42 | 121.0K | 100,000 | — | ↗ |
| 2023-01-26 | RODRIGUEZ RAUL R | Director | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 2.42 | 484.0K | 400,000 | — | ↗ |
| 2023-01-26 | Dummer Wolfgang | Director | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 2.42 | 121.0K | 100,000 | — | ↗ |
| 2022-12-28 | Schorno Dean L | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-12-28 | Santos David A | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-12-28 | RODRIGUEZ RAUL R | Director | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2022-12-28 | Dummer Wolfgang | Director | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-12-09 | Furey Raymond J. | Director | — | D | Employee Stock Option (right to buy) | 187,500 | 0.90 | 168.1K | — | — | ↗ |
| 2022-09-14 | VANCE DOLLY | Officer | A-Award | A | Employee Stock Option (right to buy) | 81,250 | 2.00 | 162.5K | 81,250 | — | ↗ |
| 2022-09-14 | Schorno Dean L | Officer | A-Award | A | Employee Stock Option (right to buy) | 81,250 | 2.00 | 162.5K | 81,250 | — | ↗ |
| 2022-09-14 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 300,000 | 2.00 | 600.0K | 300,000 | — | ↗ |
| 2022-06-09 | RODRIGUEZ RAUL R | Officer | P-Purchase | A | Common Stock | 1,000,000 | 0.69 | 688.4K | 1,391,776 | — | ↗ |
| 2022-05-20 | Wasman Jane | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-05-20 | MOOS WALTER H | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-05-20 | LYONS GARY A | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.01 | 60.3K | 30,000 | — | ↗ |
| 2022-05-20 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.01 | 60.3K | 30,000 | — | ↗ |
| 2022-05-20 | Kotzin Brian L. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.01 | 60.3K | 30,000 | — | ↗ |
| 2022-05-20 | HANNAH ALISON L. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-05-20 | Ali-Jackson Kamil | Director | A-Award | A | Stock Option (Right to Buy) | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2022-01-24 | VANCE DOLLY | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 60,260 | — | ↗ |
| 2022-01-24 | Schorno Dean L | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 2.42 | 242.0K | 100,000 | — | ↗ |
| 2022-01-24 | Santos David A | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-01-24 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 391,776 | — | ↗ |
| 2022-01-24 | Dummer Wolfgang | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 67,848 | — | ↗ |
| 2021-12-16 | Ali-Jackson Kamil | Director | A-Award | A | Stock Option (Right to Buy) | 120,000 | 2.44 | 292.8K | 120,000 | — | ↗ |
| 2021-11-04 | VANCE DOLLY | Officer | A-Award | A | Stock Option (Right to Buy) | 81,250 | 2.00 | 162.5K | 81,250 | — | ↗ |
| 2021-11-04 | Schorno Dean L | Officer | A-Award | A | Stock Option (Right to Buy) | 81,250 | 2.00 | 162.5K | 81,250 | — | ↗ |
| 2021-11-04 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 2.00 | 600.0K | 300,000 | — | ↗ |
| 2021-11-04 | Dummer Wolfgang | Officer | A-Award | A | Stock Option (Right to Buy) | 37,500 | 2.38 | 89.3K | 37,500 | — | ↗ |
| 2021-05-19 | Wasman Jane | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2021-05-19 | MOOS WALTER H | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.64 | 109.2K | 30,000 | — | ↗ |
| 2021-05-19 | LYONS GARY A | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2021-05-19 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2021-05-19 | Kotzin Brian L. | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2021-05-19 | Katkin Keith | Director | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2021-05-19 | HANNAH ALISON L. | Director | A-Award | A | Common Stock | 6,250 | 0.00 | — | 6,250 | — | ↗ |
| 2021-05-19 | Goodwin Bradford S | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.64 | 109.2K | 30,000 | — | ↗ |
| 2021-05-14 | HANNAH ALISON L. | Director | A-Award | A | Stock Option (Right to Buy) | 80,000 | 3.71 | 296.8K | 80,000 | — | ↗ |
| 2021-04-01 | VANCE DOLLY | Officer | A-Award | A | Stock Option (Right to Buy) | 37,500 | 2.42 | 90.8K | 37,500 | — | ↗ |
| 2021-04-01 | Schorno Dean L | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 2.42 | 121.0K | 50,000 | — | ↗ |
| 2021-04-01 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 162,500 | 2.42 | 393.3K | 162,500 | — | ↗ |
| 2021-01-27 | VANCE DOLLY | Officer | A-Award | A | Stock Option(right to buy) | 125,000 | 3.54 | 442.5K | 125,000 | — | ↗ |
| 2021-01-27 | Schorno Dean L | Officer | A-Award | A | Stock Option(right to buy) | 112,500 | 3.54 | 398.3K | 112,500 | — | ↗ |
| 2021-01-27 | Santos David A | Officer | A-Award | A | Stock Option(right to buy) | 137,500 | 3.54 | 486.8K | 137,500 | — | ↗ |
| 2021-01-27 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Stock Option(right to buy) | 525,000 | 3.54 | 1.86M | 525,000 | — | ↗ |
| 2021-01-27 | Dummer Wolfgang | Officer | A-Award | A | Stock Option(right to buy) | 125,000 | 3.54 | 442.5K | 125,000 | — | ↗ |
| 2020-08-19 | Santos David A | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 250,000 | 2.52 | 630.0K | 250,000 | — | ↗ |
| 2020-08-10 | Santos David A | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-05-15 | Wasman Jane | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 1.77 | 97.1K | 55,000 | — | ↗ |
| 2020-05-15 | MOOS WALTER H | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 1.77 | 97.1K | 55,000 | — | ↗ |
| 2020-05-15 | LYONS GARY A | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 1.77 | 97.1K | 55,000 | — | ↗ |
| 2020-05-15 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 1.77 | 97.1K | 55,000 | — | ↗ |
| 2020-05-15 | Kotzin Brian L. | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 1.77 | 97.1K | 55,000 | — | ↗ |
| 2020-05-15 | Katkin Keith | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 1.77 | 97.1K | 55,000 | — | ↗ |
| 2020-05-15 | Goodwin Bradford S | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 1.77 | 97.1K | 55,000 | — | ↗ |
| 2020-05-14 | Cabatuan Nelson | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.75 | 35.0K | 20,000 | — | ↗ |
| 2020-02-06 | VANCE DOLLY | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 2.42 | 363.0K | 150,000 | — | ↗ |
| 2020-02-06 | Schorno Dean L | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 2.42 | 484.0K | 200,000 | — | ↗ |
| 2020-02-06 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Stock Option (right to buy) | 650,000 | 2.42 | 1.57M | 650,000 | — | ↗ |
| 2020-02-06 | Cabatuan Nelson | Officer | A-Award | A | Stock Option (right to buy) | 90,000 | 2.42 | 217.8K | 90,000 | — | ↗ |
| 2019-11-18 | VANCE DOLLY | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 4.49 | 336.8K | 75,000 | — | ↗ |
| 2019-11-18 | Schorno Dean L | Officer | A-Award | A | Employee Stock Option (right to buy) | 83,750 | 3.44 | 288.1K | 83,750 | — | ↗ |
| 2019-11-18 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 237,500 | 4.49 | 1.07M | 237,500 | — | ↗ |
| 2019-11-18 | Mayer Eldon C. III | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 4.49 | 336.8K | 75,000 | — | ↗ |
| 2019-11-18 | Masuda Esteban | Officer | S-Sale | A | Employee Stock Option (right to buy) | 62,500 | 4.49 | 280.6K | 62,500 | — | ↗ |
| 2019-11-18 | Lasaga Joseph | Officer | A-Award | A | Employee Stock Option (right to buy) | 43,750 | 4.49 | 196.4K | 43,750 | — | ↗ |
| 2019-11-18 | Dummer Wolfgang | Officer | A-Award | A | Employee Stock Option (right to buy) | 220,000 | 2.25 | 495.0K | 220,000 | — | ↗ |
| 2019-11-04 | Dummer Wolfgang | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-05-23 | Wasman Jane | Director | A-Award | A | Stock Option (Right to Buy) | 13,750 | 2.02 | 27.8K | 13,750 | — | ↗ |
| 2019-05-23 | MOOS WALTER H | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.02 | 111.1K | 55,000 | — | ↗ |
| 2019-05-23 | LYONS GARY A | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.02 | 111.1K | 55,000 | — | ↗ |
| 2019-05-23 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.02 | 111.1K | 55,000 | — | ↗ |
| 2019-05-23 | Kotzin Brian L. | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.02 | 111.1K | 55,000 | — | ↗ |
| 2019-05-23 | Katkin Keith | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.02 | 111.1K | 55,000 | — | ↗ |
| 2019-05-23 | Goodwin Bradford S | Director | A-Award | A | Stock Option (Right to Buy) | 55,000 | 2.02 | 111.1K | 55,000 | — | ↗ |
| 2019-05-22 | Schorno Dean L | Officer | P-Purchase | A | Common Stock | 3,274 | 2.13 | 7.0K | 50,000 | — | ↗ |
| 2019-04-01 | Wasman Jane | Director | A-Award | A | Stock Option ( Right to Buy) | 80,000 | 2.42 | 193.6K | 80,000 | — | ↗ |
| 2019-03-20 | VANCE DOLLY | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 4.49 | 336.8K | 75,000 | — | ↗ |
| 2019-03-20 | Schorno Dean L | Officer | A-Award | A | Employee Stock Option (right to buy) | 83,750 | 3.44 | 288.1K | 83,750 | — | ↗ |
| 2019-03-20 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 237,500 | 4.49 | 1.07M | 237,500 | — | ↗ |
| 2019-03-20 | Mayer Eldon C. III | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 4.49 | 336.8K | 75,000 | — | ↗ |
| 2019-03-20 | Masuda Esteban | Officer | A-Award | A | Employee Stock Option (right to buy) | 62,500 | 4.49 | 280.6K | 62,500 | — | ↗ |
| 2019-03-20 | Markel Stacy | Officer | A-Award | A | Employee Stock Option (right to buy) | 62,500 | 3.94 | 246.3K | 62,500 | — | ↗ |
| 2019-03-20 | Lasaga Joseph | Officer | A-Award | A | Employee Stock Option (right to buy) | 43,750 | 4.49 | 196.4K | 43,750 | — | ↗ |
| 2019-03-20 | Duliege Anne-Marie | Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 4.49 | 336.8K | 75,000 | — | ↗ |
| 2019-01-23 | VANCE DOLLY | Officer | A-Award | A | Employee Stock Option (right to buy) | 162,500 | 2.00 | 325.0K | 162,500 | — | ↗ |
| 2019-01-23 | Schorno Dean L | Officer | A-Award | A | Employee Stock Option (right to buy) | 162,500 | 2.00 | 325.0K | 162,500 | — | ↗ |
| 2019-01-23 | RODRIGUEZ RAUL R | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 600,000 | 2.00 | 1.20M | 600,000 | — | ↗ |
| 2019-01-23 | Mayer Eldon C. III | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 2.00 | 400.0K | 200,000 | — | ↗ |
| 2019-01-23 | Masuda Esteban | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 2.00 | 200.0K | 100,000 | — | ↗ |
| 2019-01-23 | Markel Stacy | Officer | A-Award | A | Employee Stock Option (right to buy) | 137,500 | 2.00 | 275.0K | 137,500 | — | ↗ |
| 2019-01-23 | Lasaga Joseph | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 2.00 | 200.0K | 100,000 | — | ↗ |
| 2019-01-23 | Duliege Anne-Marie | Officer | A-Award | A | Employee Stock Option (right to buy) | 162,500 | 2.00 | 325.0K | 162,500 | — | ↗ |
| 2019-01-23 | Cabatuan Nelson | Officer | A-Award | A | Employee Stock Option (right to buy) | 60,000 | 2.00 | 120.0K | 60,000 | — | ↗ |
| 2018-10-12 | Cabatuan Nelson | Officer | S-Sale | D | Common Stock | 10,000 | 3.12 | 31.2K | 58 | — | ↗ |
| 2018-09-17 | Duliege Anne-Marie | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 37,500 | 2.11 | 79.1K | 112,500 | — | ↗ |
| 2018-09-11 | Mayer Eldon C. III | Officer | P-Purchase | A | Common Stock | 50,000 | 3.23 | 161.3K | 215,000 | — | ↗ |
| 2018-09-10 | Mayer Eldon C. III | Officer | P-Purchase | A | Common Stock | 50,000 | 3.28 | 164.2K | 165,000 | — | ↗ |
| 2018-09-04 | Duliege Anne-Marie | Officer | M-Exempt | D | Employe Stock Option (right to buy) | 16,500 | 2.54 | 41.9K | 383,500 | — | ↗ |
| 2018-08-23 | Mayer Eldon C. III | Officer | P-Purchase | A | Common Stock | 100,000 | 2.82 | 282.3K | 115,000 | — | ↗ |
| 2018-08-17 | RODRIGUEZ RAUL R | Director / Officer | P-Purchase | A | Common Stock | 114,000 | 2.63 | 300.0K | 173,519 | — | ↗ |
| 2018-08-14 | Cabatuan Nelson | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 20,000 | 2.76 | 55.2K | 20,000 | — | ↗ |
| 2018-07-02 | Duliege Anne-Marie | Officer | S-Sale | D | Common Stock | 5,000 | 2.79 | 13.9K | 0 | — | ↗ |
| 2018-06-04 | Schorno Dean L | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 167,500 | 3.44 | 576.2K | 167,500 | — | ↗ |
| 2018-05-29 | Schorno Dean L | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-05-17 | RINGROSE PETER S | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.98 | 159.2K | 40,000 | — | ↗ |
| 2018-05-17 | MOOS WALTER H | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.98 | 159.2K | 40,000 | — | ↗ |
| 2018-05-17 | LYONS GARY A | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.98 | 159.2K | 40,000 | — | ↗ |
| 2018-05-17 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.98 | 119.4K | 30,000 | — | ↗ |
| 2018-05-17 | Kotzin Brian L. | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.98 | 159.2K | 40,000 | — | ↗ |
| 2018-05-17 | Katkin Keith | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.98 | 159.2K | 40,000 | — | ↗ |
| 2018-05-17 | Goodwin Bradford S | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.98 | 159.2K | 40,000 | — | ↗ |
| 2018-05-09 | VANCE DOLLY | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 2.11 | 316.5K | 150,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
742.2K
Shares Outstanding
18.48M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Raul R. Rodriguez President and Chief Executive Officer | 787.4K | — | 951.3K | 2.24M | 634.6K | 43.9K | 4.66M | 68.53% | ↗ |
| 2 | 2025 | David A. Santos Executive Vice President and Chief Commercial Officer | 515.9K | — | 443.4K | 522.8K | 308.8K | 40.6K | 1.83M | 52.76% | ↗ |
| 3 | 2025 | Lisa Rojkjaer, M.D. Executive Vice President and Chief Medical Officer | 517.3K | — | 443.4K | 522.8K | 294.3K | 52.3K | 1.83M | 52.80% | ↗ |
| 4 | 2025 | Dean L. Schorno Executive Vice President and Chief Financial Officer | 515.0K | — | 443.4K | 522.8K | 300.7K | 40.4K | 1.82M | 53.02% | ↗ |
| 5 | 2025 | Raymond J. Furey Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 480.5K | — | 443.4K | 522.8K | 287.8K | 34.9K | 1.77M | 54.61% | ↗ |
| 6 | 2024 | Raul R. Rodriguez President and Chief Executive Officer | 757.0K | — | 508.0K | 1.18M | 522.3K | 36.2K | 3.00M | 56.13% | ↗ |
| 7 | 2024 | David A. Santos Executive Vice President and Chief Commercial Officer | 496.1K | — | 265.4K | 307.5K | 277.8K | 35.6K | 1.38M | 41.44% | ↗ |
| 8 | 2024 | Dean L. Schorno Executive Vice President and Chief Financial Officer | 495.1K | — | 265.4K | 307.5K | 273.6K | 36.2K | 1.38M | 41.58% | ↗ |
| 9 | 2024 | Raymond J. Furey Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 462.0K | — | 265.4K | 307.5K | 255.3K | 34.4K | 1.32M | 43.25% | ↗ |
| 10 | 2024 | Lisa Rojkjaer, M.D. Executive Vice President and Chief Medical Officer | 401.3K | 50.0K | — | 430.9K | 221.0K | 29.8K | 1.13M | 38.03% | ↗ |
| 11 | 2023 | Raul R. Rodriguez President and Chief Executive Officer | 728.0K | — | 561.0K | 1.71M | 415.0K | 30.6K | 3.44M | 65.89% | ↗ |
| 12 | 2023 | David A. Santos Executive Vice President and Chief Commercial Officer | 477.0K | — | 149.6K | 455.0K | 230.2K | 30.0K | 1.34M | 45.06% | ↗ |
| 13 | 2023 | Dean L. Schorno Executive Vice President and Chief Financial Officer | 476.1K | — | 117.8K | 355.5K | 229.7K | 30.9K | 1.21M | 39.11% | ↗ |
| 14 | 2023 | Wolfgang Dummer Former Executive Vice President and Chief Medical Officer | 125.0K | — | 22.4K | 436.9K | — | 491.1K | 1.08M | 42.71% | ↗ |
| 15 | 2023 | Raymond J. Furey Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 440.0K | — | — | — | 212.3K | 30.7K | 683.0K | 0.00% | ↗ |
| 16 | 2022 | Raul R. Rodriguez President and Chief Executive Officer | 700.0K | — | 484.0K | 1.29M | 365.4K | 27.6K | 2.86M | 61.84% | ↗ |
| 17 | 2022 | Dolly A. Vance Former Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary | 437.3K | — | 129.9K | 958.6K | — | 749.6K | 2.28M | 47.84% | ↗ |
| 18 | 2022 | Wolfgang Dummer Former Executive Vice President and Chief Medical Officer | 490.0K | 100.0K | 121.0K | 321.8K | 222.7K | 27.4K | 1.28M | 34.52% | ↗ |
| 19 | 2022 | Wolfgang Dummer Executive Vice President and Chief Medical Officer | 490.0K | 100.0K | 121.0K | 780.00 | 222.7K | 27.4K | 1.28M | 9.49% | ↗ |
| 20 | 2022 | Dean L. Schorno Executive Vice President and Chief Financial Officer | 460.0K | — | 121.0K | 321.8K | 209.1K | 27.6K | 1.14M | 38.86% | ↗ |
| 21 | 2022 | David A. Santos Executive Vice President and Chief Commercial Officer | 450.0K | — | 121.0K | 321.8K | 204.5K | 27.1K | 1.12M | 39.38% | ↗ |
| 22 | 2022 | Raymond J. Furey Executive Vice President, General Counsel and Corporate Secretary | 49.4K | — | — | 292.5K | — | 358.00 | 342.3K | 85.46% | ↗ |
| 23 | 2022 | Raymond J. Furey Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | 49.4K | — | — | 292.5K | — | 358.00 | 342.3K | 85.46% | ↗ |
| 24 | 2021 | Raul R. Rodriguez President and Chief Executive Officer | 662.3K | — | — | 2.45M | 298.0K | 19.1K | 3.43M | 71.43% | ↗ |
| 25 | 2021 | Dolly A. Vance Former Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary | 524.9K | — | — | 583.0K | 256.5K | 28.7K | 1.39M | 41.85% | ↗ |
| 26 | 2021 | Dolly A. Vance Executive Vice President, Corporate Affairs, General | 524.9K | — | — | 583.0K | 256.5K | 28.7K | 1.39M | 41.85% | ↗ |
| 27 | 2021 | David A. Santos Executive Vice President and Chief Commercial Officer | 425.4K | — | — | 641.3K | 169.1K | 6.2K | 1.24M | 51.64% | ↗ |
| 28 | 2021 | Wolfgang Dummer Executive Vice President and Chief Medical Officer | 454.1K | — | — | 583.0K | 183.9K | 6.1K | 1.23M | 47.51% | ↗ |
| 29 | 2021 | Wolfgang Dummer, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 454.1K | — | — | 583.0K | 183.9K | 6.1K | 1.23M | 47.51% | ↗ |
| 30 | 2021 | Wolfgang Dummer Former Executive Vice President and Chief Medical Officer | 454.1K | — | — | 583.0K | 183.9K | 6.1K | 1.23M | 47.51% | ↗ |
| 31 | 2021 | Dean L. Schorno Executive Vice President and Chief Financial Officer | 437.1K | — | — | 524.7K | 180.3K | 6.1K | 1.15M | 45.70% | ↗ |
| 32 | 2020 | Raul R. Rodriguez President and Chief Executive Officer | 662.3K | — | — | 1.99M | 298.0K | 10.8K | 2.96M | 67.23% | ↗ |
| 33 | 2020 | Dean L. Schorno Executive Vice President and Chief Financial Officer | 424.4K | — | — | 613.2K | 156.0K | 9.1K | 1.20M | 50.99% | ↗ |
| 34 | 2020 | Dolly A. Vance Executive Vice President, Corporate Affairs, General | 524.9K | — | — | 459.9K | 200.8K | 9.1K | 1.19M | 38.50% | ↗ |
| 35 | 2020 | Dolly A. Vance Former Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary | 524.9K | — | — | 459.9K | 200.8K | 9.1K | 1.19M | 38.50% | ↗ |
| 36 | 2020 | David A. Santos Executive Vice President and Chief Commercial Officer | 163.7K | — | — | 819.9K | 155.6K | 51.4K | 1.19M | 68.86% | ↗ |
| 37 | 2020 | Wolfgang Dummer Executive Vice President and Chief Medical Officer | 440.0K | — | — | 116.0K | 165.0K | 9.4K | 730.4K | 15.89% | ↗ |
| 38 | 2020 | Wolfgang Dummer, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 440.0K | — | — | 116.0K | 165.0K | 9.4K | 393.00 | 29,524.17% | ↗ |
| 39 | 2019 | Raul R. Rodriguez President and Chief Executive Officer | 649.3K | — | — | 1.55M | 350.6K | 9.0K | 2.56M | 60.63% | ↗ |
| 40 | 2019 | Anne-Marie Duliege Executive Vice President, Chief Medical Officer | 309.8K | — | — | 420.7K | — | 869.5K | 1.60M | 26.29% | ↗ |
| 41 | 2019 | Dolly A. Vance Executive Vice President, Corporate Affairs, General | 514.6K | — | — | 420.7K | 239.3K | 7.4K | 1.18M | 35.59% | ↗ |
| 42 | 2019 | Dean L. Schorno Executive Vice President and Chief Financial Officer | 412.0K | — | — | 420.7K | 191.6K | 9.0K | 1.03M | 40.72% | ↗ |
| 43 | 2019 | Eldon C. Mayer, III Executive Vice President, Chief Commercial Officer | 406.9K | — | — | 517.8K | — | 9.0K | 933.6K | 55.46% | ↗ |
| 44 | 2019 | Esteban Masuda, Ph.D. Executive Vice President, Research | 360.6K | — | — | 258.9K | 167.7K | 9.0K | 796.1K | 32.52% | ↗ |
| 45 | 2019 | Wolfgang Dummer, M.D., Ph.D. Executive Vice President and Chief Medical Officer | 69.9K | — | — | 608.9K | — | 100.3K | 779.1K | 78.15% | ↗ |
| 46 | 2018 | Raul R. Rodriguez President and Chief Executive Officer | 636.5K | — | — | 2.73M | 607.7K | 3.4K | 3.98M | 68.66% | ↗ |
| 47 | 2018 | Dolly A. Vance Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary | 504.5K | — | — | 863.1K | 401.4K | 1.8K | 1.77M | 48.74% | ↗ |
| 48 | 2018 | Dolly A. Vance Executive Vice President, Corporate Affairs, General | 504.5K | — | — | 863.1K | 401.4K | 1.8K | 1.77M | 48.74% | ↗ |
| 49 | 2018 | Anne-Marie Duliege Executive Vice President, Chief Medical Officer | 463.5K | — | — | 863.1K | 368.8K | 3.4K | 1.70M | 50.81% | ↗ |
| 50 | 2018 | Eldon C. Mayer, III Executive Vice President, Chief Commercial Officer | 400.0K | — | — | 863.1K | 317.8K | 3.4K | 1.58M | 54.48% | ↗ |
| 51 | 2018 | Esteban Masuda, Ph.D. Executive Vice President, Research | 350.1K | — | — | 719.3K | 227.6K | 3.3K | 1.30M | 55.32% | ↗ |
| 52 | 2018 | Dean L. Schorno Executive Vice President and Chief Financial Officer | 237.8K | — | — | 749.7K | 154.6K | 52.1K | 1.19M | 62.78% | ↗ |
| 53 | 2017 | Raul R. Rodriguez President and Chief Executive Officer | 618.0K | — | — | 1.18M | 370.8K | 3.4K | 2.17M | 54.34% | ↗ |
| 54 | 2017 | Dolly A. Vance Executive Vice President, Corporate Affairs, General | 489.8K | — | — | 393.5K | 244.9K | 1.8K | 1.13M | 34.83% | ↗ |
| 55 | 2017 | Dolly A. Vance Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary | 489.8K | — | — | 393.5K | 244.9K | 1.8K | 1.13M | 34.83% | ↗ |
| 56 | 2017 | Ryan D. Maynard Former Executive Vice President, Chief Financial Officer | 454.6K | — | — | 393.5K | 227.3K | 1.2K | 1.08M | 36.55% | ↗ |
| 57 | 2017 | Anne-Marie Duliege Executive Vice President, Chief Medical Officer | 450.0K | — | — | 393.5K | 225.0K | 3.4K | 1.07M | 36.71% | ↗ |
| 58 | 2017 | Eldon C. Mayer, III Executive Vice President, Chief Commercial Officer | 385.0K | — | — | 131.2K | 192.5K | 3.4K | 712.0K | 18.42% | ↗ |
| 59 | 2017 | Esteban Masuda, Ph.D. Executive Vice President, Research | 336.0K | — | — | 131.2K | 168.0K | 3.2K | 638.4K | 20.55% | ↗ |
| 60 | 2016 | Raul R. Rodriguez President and Chief Executive Officer | 618.0K | — | — | 1.32M | 241.0K | 3.4K | 2.18M | 60.41% | ↗ |
| 61 | 2016 | Anne-Marie Duliege Executive Vice President, Chief Medical Officer | 358.2K | — | — | 604.8K | 120.2K | 62.8K | 1.15M | 52.78% | ↗ |
| 62 | 2016 | Dolly A. Vance Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary | 489.8K | — | — | 493.4K | 159.2K | 1.8K | 1.14M | 43.12% | ↗ |
| 63 | 2016 | Eldon C. Mayer, III Executive Vice President, Chief Commercial Officer | 86.6K | — | — | 962.1K | 28.5K | 60.8K | 1.14M | 84.54% | ↗ |
| 64 | 2016 | Ryan D. Maynard Executive Vice President, Chief Financial Officer | 454.6K | — | — | 493.4K | 147.7K | 1.2K | 1.10M | 44.98% | ↗ |
| 65 | 2016 | Ryan D. Maynard Former Executive Vice President, Chief Financial Officer | 454.6K | — | — | 493.4K | 147.7K | 1.2K | 1.10M | 44.98% | ↗ |
| 66 | 2015 | Raul R. Rodriguez President and Chief Executive Officer | 600.0K | — | — | 1.23M | 306.0K | 3.9K | 2.14M | 57.40% | ↗ |
| 67 | 2015 | Donald G. Payan, M.D. Executive Vice President, of Discovery and Research | 559.6K | — | — | 544.8K | 237.8K | 9.9K | 1.35M | 40.29% | ↗ |
| 68 | 2015 | Elliott B. Grossbard, M.D. Former Executive Vice President, Chief Medical Officer | 521.3K | — | — | 476.7K | 221.6K | 9.9K | 1.23M | 38.77% | ↗ |
| 69 | 2015 | Dolly A. Vance Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary | 475.5K | — | — | 476.7K | 202.1K | 2.3K | 1.16M | 41.21% | ↗ |
| 70 | 2015 | Ryan D. Maynard Executive Vice President, Chief Financial Officer | 441.3K | — | — | 476.7K | 187.6K | 1.2K | 1.11M | 43.07% | ↗ |
| 71 | 2015 | Ryan D. Maynard Former Executive Vice President, Chief Financial Officer | 441.3K | — | — | 476.7K | 187.6K | 1.2K | 1.11M | 43.07% | ↗ |
| 72 | 2014 | James M. Gower Former Chief Executive Officer, Chairman of the Board and | 695.1K | — | — | 657.2K | — | 9.9K | 1.36M | 48.24% | ↗ |
| 73 | 2014 | Donald G. Payan, M.D. Executive Vice President, of Discovery and Research | 559.6K | — | — | 784.3K | — | 9.9K | 1.35M | 57.93% | ↗ |
| 74 | 2014 | Donald G. Payan, M.D. Executive Vice President, President of Discovery and | 559.6K | — | — | 784.3K | — | 9.9K | 1.35M | 57.93% | ↗ |
| 75 | 2014 | Raul R. Rodriguez President and Chief Executive Officer | 551.7K | — | — | 784.3K | — | 2.2K | 1.34M | 58.61% | ↗ |
| 76 | 2014 | Raul R. Rodriguez President and Chief Executive Officer | 551.7K | — | — | 784.3K | — | 2.2K | 1.34M | 58.61% | ↗ |
| 77 | 2014 | Elliott B. Grossbard, M.D. Former Executive Vice President, Chief Medical Officer | 521.3K | — | — | 784.3K | — | 11.4K | 1.32M | 59.55% | ↗ |
| 78 | 2014 | Elliott B. Grossbard, M.D. Executive Vice President, Chief Medical Officer | 521.3K | — | — | 784.3K | — | 11.4K | 1.32M | 59.55% | ↗ |
| 79 | 2014 | Dolly A. Vance Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary | 475.5K | — | — | 653.6K | — | 3.0K | 1.13M | 57.73% | ↗ |
| 80 | 2014 | Ryan D. Maynard Executive Vice President, Chief Financial Officer | 441.3K | — | — | 653.6K | — | 3.0K | 1.10M | 59.53% | ↗ |
| 81 | 2014 | Ryan D. Maynard Executive Vice President, Chief Financial Officer | 441.3K | — | — | 653.6K | — | 3.0K | 1.10M | 59.53% | ↗ |
| 82 | 2013 | James M. Gower Former Chief Executive Officer, Chairman of the Board and | 695.1K | — | — | 1.00M | — | 9.9K | 1.71M | 58.77% | ↗ |
| 83 | 2013 | James M. Gower Chief Executive Officer, Chairman of the Board and | 695.1K | — | — | 1.00M | — | 9.9K | 1.71M | 58.77% | ↗ |
| 84 | 2013 | Donald G. Payan, M.D. Executive Vice President, President of Discovery and | 559.6K | — | — | 893.2K | — | 9.9K | 1.46M | 61.07% | ↗ |
| 85 | 2013 | Donald G. Payan, M.D. Executive Vice President, of Discovery and Research | 559.6K | — | — | 893.2K | — | 9.9K | 1.46M | 61.07% | ↗ |
| 86 | 2013 | Raul R. Rodriguez President and Chief Executive Officer | 551.7K | — | — | 669.9K | — | 1.8K | 1.22M | 54.76% | ↗ |
| 87 | 2013 | Raul R. Rodriguez President and Chief Operating Officer | 551.7K | — | — | 669.9K | — | 1.8K | 1.22M | 54.76% | ↗ |
| 88 | 2013 | Raul R. Rodriguez President and Chief Executive Officer | 551.7K | — | — | 669.9K | — | 1.8K | 1.22M | 54.76% | ↗ |
| 89 | 2013 | Elliott B. Grossbard, M.D. Former Executive Vice President, Chief Medical Officer | 521.3K | — | — | 669.9K | — | 9.9K | 1.20M | 55.77% | ↗ |
| 90 | 2013 | Elliott B. Grossbard, M.D. Executive Vice President, Chief Medical Officer | 521.3K | — | — | 669.9K | — | 9.9K | 1.20M | 55.77% | ↗ |
| 91 | 2013 | Ryan D. Maynard Executive Vice President, Chief Financial Officer | 441.3K | — | — | 669.9K | — | 780.00 | 1.11M | 60.24% | ↗ |
| 92 | 2013 | Ryan D. Maynard Executive Vice President, Chief Financial Officer | 441.3K | — | — | 669.9K | — | 780.00 | 1.11M | 60.24% | ↗ |
| 93 | 2012 | James M. Gower Former Chief Executive Officer, Chairman of the Board and | 671.6K | — | — | 1.24M | 382.8K | 5.1K | 2.30M | 53.94% | ↗ |
| 94 | 2012 | James M. Gower Chief Executive Officer, Chairman of the Board and | 671.6K | — | — | 1.24M | 382.8K | 5.1K | 2.30M | 53.94% | ↗ |
| 95 | 2012 | Donald G. Payan, M.D. Executive Vice President, President of Discovery and | 540.6K | — | — | 1.10M | 256.8K | 5.1K | 1.91M | 57.88% | ↗ |
| 96 | 2012 | Raul R. Rodriguez President and Chief Executive Officer | 533.1K | — | — | 827.1K | 303.8K | 1.8K | 1.67M | 49.65% | ↗ |
| 97 | 2012 | Raul R. Rodriguez President and Chief Operating Officer | 533.1K | — | — | 827.1K | 303.8K | 1.8K | 1.67M | 49.65% | ↗ |
| 98 | 2012 | Elliott B. Grossbard, M.D. Executive Vice President, Chief Medical Officer | 503.7K | — | — | 827.1K | 239.3K | 5.1K | 1.58M | 52.51% | ↗ |
| 99 | 2012 | Ryan D. Maynard Executive Vice President, Chief Financial Officer | 426.4K | — | — | 827.1K | 202.6K | 780.00 | 1.46M | 56.77% | ↗ |
| 100 | 2011 | James M. Gower Chief Executive Officer, Chairman of the Board and | 648.9K | — | — | 322.1K | 467.2K | 5.1K | 1.44M | 22.32% | ↗ |
| 101 | 2011 | Raul R. Rodriguez President and Chief Operating Officer | 515.0K | — | — | 322.1K | 370.8K | 2.2K | 1.21M | 26.62% | ↗ |
| 102 | 2011 | Donald G. Payan, M.D. Executive Vice President, President of Discovery and | 522.4K | — | — | 322.1K | 313.4K | 5.1K | 1.16M | 27.69% | ↗ |
| 103 | 2011 | Elliott B. Grossbard, M.D. Executive Vice President, Chief Medical Officer | 486.7K | — | — | 322.1K | 292.0K | 5.1K | 1.11M | 29.12% | ↗ |
| 104 | 2011 | Ryan D. Maynard Executive Vice President, Chief Financial Officer | 412.0K | — | — | 322.1K | 247.2K | 780.00 | 982.1K | 32.80% | ↗ |
| 105 | 2010 | James M. Gower Chief Executive Officer, Chairman of the Board and | 630.0K | — | — | 1.58M | 302.4K | 3.6K | 2.52M | 62.86% | ↗ |
| 106 | 2010 | Raul R. Rodriguez President and Chief Operating Officer | 488.6K | — | — | 1.76M | 240.0K | 1.6K | 2.49M | 70.63% | ↗ |
| 107 | 2010 | Donald G. Payan, M.D. Executive Vice President, President of Discovery and | 507.2K | — | — | 1.19M | 202.9K | 3.6K | 1.90M | 62.47% | ↗ |
| 108 | 2010 | Ryan D. Maynard Executive Vice President, Chief Financial Officer | 383.6K | — | — | 1.20M | 160.0K | 540.00 | 1.74M | 68.78% | ↗ |
| 109 | 2010 | Elliott B. Grossbard, M.D. Executive Vice President, Chief Medical Officer | 472.5K | — | — | 827.9K | 189.0K | 3.6K | 1.49M | 55.45% | ↗ |
| 110 | 2009 | James M. Gower Chief Executive Officer, Chairman of the Board and | 600.0K | — | — | 890.7K | 504.0K | 3.6K | 2.00M | 44.57% | ↗ |
| 111 | 2009 | Donald G. Payan, M.D. Executive Vice President, President of Discovery and | 483.0K | — | — | 679.7K | 338.1K | 3.6K | 1.50M | 45.18% | ↗ |
| 112 | 2009 | Raul R. Rodriguez President and Chief Operating Officer | 430.0K | — | — | 539.1K | 430.0K | 810.00 | 1.40M | 38.51% | ↗ |
| 113 | 2009 | Elliott B. Grossbard, M.D. Executive Vice President, Chief Medical Officer | 450.0K | — | — | 539.1K | 315.0K | 3.6K | 1.31M | 41.23% | ↗ |
| 114 | 2009 | Ryan D. Maynard Executive Vice President, Chief Financial Officer | 300.0K | — | — | 703.2K | 168.0K | 540.00 | 1.17M | 60.01% | ↗ |
| 115 | 2008 | Elliott B. Grossbard, M.D., Executive Vice President, Chief Medical Officer | 600.0K | — | — | — | — | 3.7K | 4.17M | 0.00% | ↗ |
| 116 | 2008 | James M. Gower, Chief Executive Officer, Chairman of the Board and Director | 600.0K | — | — | 3.14M | — | 3.7K | 3.74M | 83.87% | ↗ |
| 117 | 2008 | Ryan D. Maynard, Vice President, Chief Financial Officer | 483.0K | — | — | — | — | 3.7K | 3.35M | 0.00% | ↗ |
| 118 | 2008 | Donald G. Payan, M.D., Executive Vice President, Chief Scientific Officer and Director | 483.0K | — | — | 2.66M | — | 3.7K | 3.15M | 84.55% | ↗ |
| 119 | 2008 | Elliott B. Grossbard, M.D., Executive Vice President, Chief Medical Officer | 450.0K | — | — | 2.47M | — | 3.7K | 2.93M | 84.50% | ↗ |
| 120 | 2008 | Raul R. Rodriguez, Executive Vice President and Chief Operating Officer | 430.0K | — | — | 2.38M | — | 844.00 | 2.81M | 84.66% | ↗ |
| 121 | 2008 | Ryan D. Maynard, Vice President, Chief Financial Officer | 300.0K | — | — | 1.43M | — | 506.00 | 1.73M | 82.60% | ↗ |
| 122 | 2007 | Donald G. Payan, M.D., Executive Vice President, President of Discovery and | 500.0K | 300.0K | — | — | 300.0K | 2.4K | 2.68M | 0.00% | ↗ |
| 123 | 2007 | Raul R. Rodriguez, Executive Vice President and Chief Operating Officer | 420.0K | 210.0K | — | — | 210.0K | 2.4K | 1.83M | 0.00% | ↗ |
| 124 | 2007 | James M. Gower, Chief Executive Officer, Chairman of the Board and Director | 500.0K | 300.0K | — | 716.1K | 300.0K | 2.4K | 1.82M | 39.38% | ↗ |
| 125 | 2007 | Donald G. Payan, M.D., Executive Vice President, Chief Scientific Officer and Director | 420.0K | 210.0K | — | 572.8K | 210.0K | 2.4K | 1.42M | 40.48% | ↗ |
| 126 | 2007 | Raul R. Rodriguez, Executive Vice President and Chief Operating Officer | 380.0K | 190.0K | — | 572.8K | 190.0K | 841.00 | 1.33M | 42.95% | ↗ |
| 127 | 2007 | Elliott B. Grossbard, M.D., Executive Vice President, Chief Medical Officer | 390.0K | 175.5K | — | 572.8K | 175.5K | 2.4K | 1.32M | 43.52% | ↗ |
| 128 | 2007 | Ryan D. Maynard, Vice President, Chief Financial Officer | 260.0K | 104.0K | — | 765.5K | 104.0K | 501.00 | 1.23M | 62.04% | ↗ |
| 129 | 2006 | James M. Gower, Chief Executive Officer, Chairman of the Board and Director | 455.0K | — | — | 1.89M | 150.2K | 2.3K | 2.50M | 75.69% | ↗ |
| 130 | 2006 | James M. Gower, Chief Executive Officer, Chairman of the Board | 455.0K | — | — | — | 150.2K | 2.3K | 2.50M | 0.00% | ↗ |
| 131 | 2006 | Elliott B. Grossbard, M.D., Executive Vice President, Chief Medical Officer | 395.0K | — | — | — | 130.4K | 2.3K | 1.64M | 0.00% | ↗ |
| 132 | 2006 | Donald G. Payan, M.D., Executive Vice President, Chief Scientific Officer and Director | 395.0K | — | — | 1.12M | 130.4K | 2.3K | 1.64M | 67.92% | ↗ |
| 133 | 2006 | Raul R. Rodriguez, Executive Vice President and Chief Operating Officer | 355.0K | — | — | 1.14M | 117.2K | 807.00 | 1.61M | 70.62% | ↗ |
| 134 | 2006 | Elliott B. Grossbard, M.D. Senior Vice President, Medical Development | 365.0K | — | — | 1.02M | 120.5K | 2.3K | 1.50M | 67.59% | ↗ |
| 135 | 2006 | Ryan D. Maynard, Vice President, Chief Financial Officer | 365.0K | — | — | — | 120.5K | 2.3K | 1.50M | 0.00% | ↗ |
| 136 | 2006 | James H. Welch, Former Vice President, Chief Financial Officer and Secretary | 280.0K | — | — | 653.8K | — | 335.00 | 934.2K | 69.99% | ↗ |
| 137 | 2006 | Ryan D. Maynard, Vice President, Chief Financial Officer | 219.6K | — | — | 486.0K | 68.2K | 420.00 | 774.1K | 62.77% | ↗ |
| 138 | 2005 | James M. Gower Chief Executive Officer, Chairman of the Board and Director | 425.0K | 100.0K | — | 215.0K | — | 966.00 | 526.0K | 40.88% | ↗ |
| 139 | 2005 | Donald G. Payan Executive Vice President and Chief Scientific Officer and Director | 370.0K | 87.0K | — | 104.3K | — | 966.00 | 458.0K | 22.76% | ↗ |
| 140 | 2005 | Elliott B. Grossbard Senior Vice President, Medical Development | 340.2K | 80.0K | — | 97.2K | — | 940.00 | 421.1K | 23.09% | ↗ |
| 141 | 2005 | Raul R. Rodriguez Executive Vice President and Chief Operating Officer | 330.0K | 78.0K | — | 67.5K | — | 911.00 | 408.9K | 16.51% | ↗ |
| 142 | 2005 | Dolly A. Vance General Counsel and Vice President of Intellectual Property | 315.0K | 74.0K | — | 118.8K | — | 869.00 | 389.9K | 30.46% | ↗ |
| 143 | 2004 | James M. Gower Chief Executive Officer, Chairman of the Board and Director | 376.5K | 66.7K | — | 80.0K | — | 1.7K | 444.9K | 17.98% | ↗ |
| 144 | 2004 | Donald G. Payan Executive Vice President and Chief Scientific Officer and Director | 355.5K | 58.4K | — | 40.0K | — | 1.6K | 415.5K | 9.63% | ↗ |
| 145 | 2004 | Elliott B. Grossbard Senior Vice President, Medical Development | 304.6K | 52.5K | — | 35.0K | — | 1.6K | 358.7K | 9.76% | ↗ |
| 146 | 2004 | Dolly A. Vance General Counsel and Vice President of Intellectual Property | 289.7K | 49.2K | — | 45.0K | — | 1.4K | 340.3K | 13.22% | ↗ |
| 147 | 2004 | Raul R. Rodriguez Executive Vice President and Chief Operating Officer | 278.4K | 50.0K | — | 75.0K | — | 1.3K | 329.8K | 22.74% | ↗ |
| 148 | 2004 | Raul R. Rodriguez Executive Vice President Chief Operating Officer | 278.4K | 50.0K | — | 75.0K | — | 1.3K | 329.8K | 22.74% | ↗ |
| 149 | 2003 | James M. Gower Chief Executive Officer, Chairman of the Board and Director | 340.5K | — | — | 270.0K | — | — | 340.5K | 79.29% | ↗ |
| 150 | 2003 | Donald G. Payan Executive Vice President and Chief Scientific Officer and Director | 309.6K | — | — | 250.0K | — | — | 309.6K | 80.74% | ↗ |
| 151 | 2003 | Elliott B. Grossbard Senior Vice President, Medical Development | 283.8K | — | — | 177.8K | — | — | 283.8K | 62.64% | ↗ |
| 152 | 2003 | Dolly A. Vance General Counsel and Vice President of Intellectual Property | 279.2K | — | — | 131.2K | — | — | 279.2K | 47.02% | ↗ |
| 153 | 2003 | Raul R. Rodriguez Executive Vice President and Chief Operating Officer | 247.7K | — | — | 193.9K | — | — | 247.7K | 78.28% | ↗ |
| 154 | 2003 | Raul R. Rodriguez Executive Vice President Chief Operating Officer | 247.7K | — | — | 193.9K | — | — | 247.7K | 78.28% | ↗ |
| 155 | 2003 | Raul R. Rodriguez Senior Vice President, Business Development and Commercial Operations | 247.7K | — | — | 193.9K | — | — | 247.7K | 78.28% | ↗ |
| 156 | 2002 | James M. Gower Chief Executive Officer, Chairman of the Board and Director | 330.0K | — | — | — | — | — | 330.0K | 0.00% | ↗ |
| 157 | 2002 | Brian C. Cunningham President and Chief Operating Officer | 300.0K | — | — | — | — | — | 300.0K | 0.00% | ↗ |
| 158 | 2002 | Donald G. Payan, MD Executive Vice President and Chief Scientific Officer and Director | 300.0K | — | — | — | — | — | 300.0K | 0.00% | ↗ |
| 159 | 2002 | Donald G. Payan Executive Vice President and Chief Scientific Officer and Director | 300.0K | — | — | — | — | — | 300.0K | 0.00% | ↗ |
| 160 | 2002 | Dolly A. Vance General Counsel and Vice President of Intellectual Property | 245.0K | — | — | — | — | — | 245.0K | 0.00% | ↗ |
| 161 | 2002 | Raul R. Rodriguez Executive Vice President Chief Operating Officer | 240.0K | — | — | — | — | — | 240.0K | 0.00% | ↗ |
| 162 | 2002 | Raul Rodriguez Senior Vice President, Business Development and Commercial Operations | 240.0K | — | — | 150.0K | — | — | 240.0K | 62.50% | ↗ |
| 163 | 2002 | Raul R. Rodriguez Senior Vice President, Business Development and Commercial Operations | 240.0K | — | — | — | — | — | 240.0K | 0.00% | ↗ |
| 164 | 2002 | Elliott B. Grossbard Senior Vice President, Medical Development | 206.3K | — | — | — | — | — | 206.3K | 0.00% | ↗ |
| 165 | 2002 | Elliot B. Grossbard, MD Senior Vice President, Medical Development | 206.3K | — | — | 250.0K | — | — | 206.3K | 121.20% | ↗ |
| 166 | 2001 | James M. Gower Chief Executive Officer, Chairman of the Board and Director | 288.8K | 50.0K | — | — | — | — | 338.8K | 0.00% | ↗ |
| 167 | 2001 | Donald G. Payan Executive Vice President and Chief Scientific Officer and Director | 263.8K | 60.0K | — | — | — | — | 323.8K | 0.00% | ↗ |
| 168 | 2001 | Donald G. Payan, MD Executive Vice President and Chief Scientific Officer and Director | 263.8K | 60.0K | — | — | — | — | 323.8K | 0.00% | ↗ |
| 169 | 2001 | Brian C. Cunningham President and Chief Operating Officer | 269.6K | 50.0K | — | — | — | — | 319.6K | 0.00% | ↗ |
| 170 | 2001 | Dolly A. Vance General Counsel and Vice President of Intellectual Property | 231.7K | — | — | — | — | — | 231.7K | 0.00% | ↗ |
| 171 | 2001 | Raul Rodriguez Senior Vice President, Business Development and Commercial Operations | 216.3K | 15.0K | — | — | — | — | 231.3K | 0.00% | ↗ |
| 172 | 2001 | Raul R. Rodriguez Senior Vice President, Business Development and Commercial Operations | 216.3K | 15.0K | — | — | — | — | 231.3K | 0.00% | ↗ |
| 173 | 2001 | Raul Rodriguez Vice President, Business Development | 216.3K | 15.0K | — | — | — | — | 231.3K | 0.00% | ↗ |
| 174 | 2001 | James H. Welch Vice President, Chief Financial Officer and Secretary | 163.3K | 30.0K | — | — | — | — | 193.3K | 0.00% | ↗ |
| 175 | 2001 | Elliot B. Grossbard, MD Senior Vice President, Medical Development | — | — | — | — | — | — | — | — | ↗ |
| 176 | 2001 | Elliott B. Grossbard Senior Vice President, Medical Development | — | — | — | — | — | — | — | — | ↗ |
| 177 | 2000 | James M. Gower Chief Executive Officer, Chairman of the Board and Director | 267.8K | — | — | — | — | — | 267.8K | 0.00% | ↗ |
| 178 | 2000 | Brian C. Cunningham President and Chief Operating Officer | 257.5K | — | — | 200.0K | — | — | 257.5K | 77.67% | ↗ |
| 179 | 2000 | Donald G. Payan, MD Executive Vice President and Chief Scientific Officer and Director | 247.2K | — | — | — | — | — | 247.2K | 0.00% | ↗ |
| 180 | 2000 | Raul Rodriguez Senior Vice President, Business Development and Commercial Operations | 165.0K | — | — | 245.0K | — | 12.2K | 177.2K | 138.24% | ↗ |
| 181 | 2000 | Raul Rodriguez Vice President, Business Development | 165.0K | — | — | 245.0K | — | 12.2K | 177.2K | 138.24% | ↗ |
| 182 | 2000 | James H. Welch Vice President, Chief Financial Officer and Secretary | 154.5K | — | — | 50.0K | — | — | 154.5K | 32.36% | ↗ |
| 183 | 2000 | Elliot B. Grossbard, MD Senior Vice President, Medical Development | — | — | — | — | — | — | — | — | ↗ |
| 184 | 1999 | James M. Gower Chief Executive Officer, Chairman of the Board and Director | 255.0K | — | — | 450.0K | — | — | 255.0K | 176.47% | ↗ |
| 185 | 1999 | Brian C. Cunningham President and Chief Operating Officer | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 186 | 1999 | Donald G. Payan, MD Executive Vice President and Chief Scientific Officer and Director | 235.4K | — | — | 150.0K | — | — | 235.4K | 63.72% | ↗ |
| 187 | 1999 | James H. Welch Vice President, Chief Financial Officer and Secretary | 100.0K | 25.0K | — | 150.0K | — | — | 125.0K | 120.00% | ↗ |
| 188 | 1999 | Raul Rodriguez Vice President, Business Development | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Raul R. Rodriguez | President, Chief Executive Officer & Director | 1M | male |
| David A. Santos | Executive Vice President & Chief Commercial Officer | 865.3K | male |
| Lisa Rojkjaer | Executive Vice President & Chief Medical Officer | 863.9K | — |
| Dean L. Schorno | Executive Vice President & Chief Financial Officer | 856.1K | male |
| Raymond J. Furey | Executive Vice President, Chief Compliance Officer, General Counsel & Corporate Secretary | 803.2K | male |
| Julie Patel | Senior Vice President of Human Resources | — | female |
| Joseph Lasaga | Executive Vice President & Chief Business Officer | — | male |
| Tarek Sallam | Vice President of Marketing | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RIGL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
